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INTRODUCTION 
Glaucoma is the second leading cause of irreversible blindness 
worldwide with an estimated 60.5 million affected by the disease in 2010 
and 12 million people estimated to be blind due to it.(1) India is home to 
12 million with Glaucoma and 1.5 million blind due to it as per the major 
prevalence studies in India in the recent past.(2–7) 
Glaucoma by definition is “a group of disorders of multifactorial 
aetiology united by a clinically characteristic optic neuropathy with 
potentially progressive clinically visible changes at the optic nerve head, 
comprising focal or generalized thinning of the neuroretinal rim with 
excavation and enlargement of the optic cup, representing 
neurodegeneration of retinal ganglion cell axons and deformation of the 
lamina cribrosa, with corresponding diffuse and localized nerve fibre 
bundle pattern visual field loss..”(8) When the treatment is considered, 
IOP reduction is the only current evidence-based treatment strategy in all 
types of glaucoma and reduction in IOP is proven to reduce the 
progression of the disease (9–14). 
According to the AAO practice guidelines, the treatment goals in 
glaucoma include achieving a stable optic nerve or retinal nerve fibre 
layer status, controlled IOP and stable visual fields while maintaining 
quality of life.(15) Most clinicians begin treatment with medical therapy 
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before considering laser or surgical therapy. This have been attributed to 
multiple clinical trials on medical therapy first showing comparable 
results to primary incisional surgery.(16,17) Ocular hypotensive therapy, 
due to the possibility of producing systemic side effects, other therapeutic 
options are currently preferred, with prostaglandin analogues being one of 
the most widely used (18) However, though multiple studies have shown 
the negative effects of long-term topical therapy on the ocular surface 
which affects the outcomes of subsequent filtration surgery, there is no 
conclusive evidence on whether prostaglandin analogues cause increased 
failure rates compared to other drugs. (19–23) It was to address these 
lacunae in medical literature the following study was conducted. 
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THEORY 
FUNCTIONAL ANATOMY 
The ciliary body, the trabecular meshwork and the uveoscleral 
pathway are the main structures involved in aqueous humour physiology.  
The ciliary body is triangular in cross-section with its apex directed 
posteriorly towards the ora serrata and the base giving rise to the iris. 
Thus it bridges the anterior and posterior segments. The 2 principal 
functions of the ciliary body are: 1. Aqueous humor formation and 2. 
Accommodation. 
It is attached at its base to the scleral spur. It is 6-7 mm wide and 
has 2 parts: 1. Pars plana (extends posteriorly from ora serrata to the 
cilary processes) and 2. Pars plicata (richly vascularised anterior part) 
consisting of radial folds called cilary processes which are the sites of 
aqueous humor formation. The ciliary processes have 2 layers of 
epithelium: inner non-pigmented layer and outer pigmented layer which 
lie with its apical surfaces apposed to each other by a complex system of 
junctions and cellular interdigitations.(24,25) The blood aqueous barrier 
is maintained by the presence of tight junctions (zonulae occludentes) 
along the lateral intercellular spaces. The non-pigmented epithelium has 
multiple basal infoldings, large nuclei, mitochondria, extensive 
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endoplasmic reticulum and Golgi complexes as they play a crucial role in 
aqueous production. 
The role of ciliary body in accommodation is brought about by the 
ciliary muscle which consists of 3 layers of fibres which function as a 
unit: 1. The outer longitudinal fibres, 2. the middle radial fibres and 3. 
The innermost circular fibres. The ciliary body is supplied by both 
sympathetic, parasympathetic and sensory nervous systems. The 
sympathetic fibres originate from the superior cervical ganglion and 
carotid plexus while the parasympathetic fibres come from the Edinger-
Westphal nucleus and pterygopalatine ganglion. The sensory fibres which 
arise from the trigeminal ganglion come via the ophthalmic nerve.(26) 
The trabecular meshwork has been described as a circular sponge 
work of tissue that is triangular in cross-section, lined by trabeculocytes 
and forms the major part of the conventional outflow system. It can be 
divided into 3 components: 1. Uveal, 2. Corneoscleral, and 3. 
Juxtacanalicular meshwork. (27) 
The uveal meshwork extends from the iris root and ciliary body to 
the peripheral cornea and forms the lateral border of the anterior chamber. 
It is composed of cord-like trabeculae with irregular apertures measuring 
between 25 to 75µm. 
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The corneoscleral meshwork extends from the scleral spur to the 
anterior wall of the scleral sulcus forming the major part of the trabecular 
meshwork. It consists of a series of thin, flat, perforated connective tissue 
sheets arranged in a laminar pattern which become progressively smaller 
nearing the Schlemm’s canal. 
The juxtacanalicular meshwork forms the outermost part and is 
composed of a layer of connective tissue line on either side by 
endothelium. The outer endothelial lining forms the inner wall of the 
Schlemm’s canal. This region contributes to maximum of the outflow 
resistance not only due its narrowness and tortuosity but also the 
resistance offered by extracellular proteoglycans and glycoproteins. (28) 
Schlemm’s canal is a circular tube lined by endothelial cells and 
surrounded by connective tissue. From the Schlemm’s canal arise around 
20-30 collector channels which drain into the deep and midscleral venous 
plexus. 
Physiology of Aqueous Humour Production and Outflow  
The aqueous humor provides a clear medium between the cornea 
and the lens, provides nutrition and removes metabolic wastes to both 
these structures. It also plays a role in neurotransmitter transport, 
homeostasis, drug transport and inflammatory reactions. The inflow and 
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outflow of aqueous humor regulates the intraocular pressure. The rate of 
inflow is approximately 2.4±0.6µL/min in the adult eye.(13)The aqueous 
humour is produced by the non-pigmented epithelium of the ciliary body 
by 3 important processes– Ultrafiltration, Active transport and Diffusion.  
The process by which fluid and its solutes cross a semipermeable 
membrane under a pressure gradient is called ultrafiltration. Diffusion is 
movement of the substance across a membrane along its concentration 
gradient. The pressure gradient here is between the capillary pressure and 
the interstitial fluid pressure (IOP) which promotes fluid movement. 
Diffusion and ultrafiltration are responsible for the accumulation of 
plasma ultrafitrate in the stroma, behind tight junctions of the non-
pigmented epithelium, from which the posterior chamber aqueous humor 
is derived 
The high concentration of colloids in the tissue space of the ciliary 
process however retards fluid movement from the stroma into the 
posterior chamber. Ultrafilration and diffusion thus can move fluid out of 
the capillaries into the stroma but by itself is not enough to produce the 
entire amount of fluid in the posterior chamber due to the resistance 
provided by the large colloidal oncotic pressure differential. Thus 
ultrafiltration moves fluid out of the cells into the stroma but requires an 
active metabolic process to bring it to the posterior chamber. (29) 
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The active transport is an energy-dependent process that selectively 
moves a substance against its electrochemical gradient across a cell 
membrane which occurs in the non-pigmented part of the ciliary 
epithelium and accounts for approximately 80% to 90% of the aqueous 
produced in the posterior chamber. (30,31) The selective trans-cellular 
transport of anions, cations and other molecules across a concentration 
gradient in the blood aqueous barrier by the non-pigmented ciliary 
epithelium creates the sufficient osmotic forces to attract water thus 
forming the aqueous humor. This is mediated by protein transporters 
distributed in the cell membrane and the energy required for the transport 
is generated by hydrolysis of adenosine triphosphate (ATP) to adenosine 
diphosphate (ADP), which is activated by Na+ and K+ mediated by Na+-
K+-ATPase, an enzyme located in both the non-pigmented and 
pigmented ciliary epithelia  
The outflow of aqueous from the eye occurs through 2 pathways. 
The conventional pathway consisting of the trabecular meshwok, passing 
through the Schlemm’s canal and reaching the aqueous and episcleral 
veins via the collector channels. The non-conventional route is formed by 
the uveoscleral pathway where the aqueous enters the connective tissue 
between the muscle bundles, passes through the suprachoroidal space and 
exits through the sclera. 
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The balance between the production and drainage of aqueous 
humor is what maintains the intraocular pressure. Elevation of IOP 
usually occurs due to the disrupted aqueous outflow through the 
convention pathway and this is a major risk factor for glaucoma.(13) 
Intraocular pressure  
Intraocular pressure which was earlier considered the aetiology 
behind glaucoma is now being recognised as the only modifiable risk 
factor and is by far not the only risk factor.(15)It is regulated by the 
aqueous outflow system which has been explained in the previous 
section. Defects in this system can arise from chronic oxidative stress 
and/or from gene mutations. (32–34)The resultant increase in IOP is 
believed to cause mechanical deformation of the cribriform plates of the 
lamina cribrosa which in turn compress the optic nerve bundle causing 
glaucomatous changes in the optic nerve.(35)The trabecular meshwork 
has been demonstrated to show cytoskeletal changes, altered cellularity 
and changes in the extracellular matrix by multiple investigators. (36–
40)It has been proven that IOP plays an important role in the neuropathy 
in POAG and reduction in the IOP reduces the risk of visual field 
progression in open-angle glaucoma.(12,14,16,17,41–44)A significant 
positive correlation has also been observed between the duration and 
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level of IOP and retinal ganglion cell loss with up to 50% loss seen 
during the initial 2-3 months of IOP elevation.(45–49) 
However, the relationship between elevated IOP and glaucomatous 
optic neuropathy is highly variable. (9–11,50) Studies have shown only 
up to 10% of patients with elevated IOP show signs of visual field loss 
and instances where up to 61% of patients with low IOP (<21 mmHg) 
show glaucomatous disc and vision field changes.(51,52). Thus IOP 
though playing a key role in the pathogenesis of glaucoma cannot be 
considered as the sole etiology as it was previously considered but rather 
an important causative dose related risk factor.  
Pathology of glaucoma 
Glaucoma is currently considered more as an optic nerve disorder 
in which the intraocular pressure is only one of the many risk factors. All 
glaucomatous optic atrophy has been described in textbooks to have the 
following features in common: 1. progressive death of retinal ganglion 
cells, 2. characteristic excavation of the optic nerve head or cupping and 
3.corresponding, functionally apparent, sequential, visual field 
deterioration in characteristic patterns. The pathophysiology of glaucoma, 
though not understood fully, is related to retinal ganglion cell death which 
is related to the intraocular pressure. The death of RGCs has been shown 
in animal eyes and patients with glaucoma as taking place in 2 phases: in 
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the first phase by apoptosis which is followed by a second phase neuronal 
loss due to the toxic effect of the degenerating axons in addition to 
continued exposure to elevated IOP. According to various theories, 
factors like elevated IOP and vascular dysregulation, contribute primarily 
in the form of obstruction to axoplasmic flow, altered laminar glial and 
connective tissue and microcirculatory changes at the laminar level 
during the initial stages. The glutamate or glycine released from the 
injured neurons and oxidative damage caused by nitric oxide and other 
reactive oxygen species causes further damage. This is followed by 
deformation and backward bending of the lamina cribrosa along with 
astrocyte and microglial activation at the ONH which results in the 
pathognomonic excavation and enlargement of the optic cup where there 
is death of the axons associated with loss of ganglion cells, with focal or 
generalized thinning and undermining of the neuroretinal rim.  
The excavation of the optic nerve head or cupping seen in 
glaucoma has been described as due to 1.loss of neural rim axons,                     
2. elongation, stretching and collapse of the laminar beams and posterior 
bowing and 3. outward, centrifugal rotation of the laminar insertion into 
the scleral insertion zone.(53,54) these structural changes to the neurons 
produce corresponding functional changes like field defects. 
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Classification of glaucoma 
Glaucoma can be classified into various types based on the 
presentation (Open angle / Closed angle), facility of aqueous outflow 
(pupillary block / without pupillary block) and presence / absence of 
other factors contributing to progressive vision and visual field loss 
(Primary / Secondary). Accurate treatment guides the treatment of 
glaucoma. 
I. Angle closure glaucoma 
A. Primary angle closure disease 
1. Natural history 
i. Primary angle closure suspect 
ii. Primary angle closure 
iii. Primary angle closure glaucoma 
2. Anterior segment mechanism of closure 
i. Iris-pupil obstruction eg. Pupillary block 
ii. Ciliary body anomalies eg. Plateau iris syndrome 
iii. Lens-pupil block eg. phacomorphic block 
B. Secondary angle closures 
1. Anterior pulling mechanisms 
i. Neovascular glaucoma 
ii. Iridocorneal endothelial syndrome 
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iii. Posterior polymorphous dystrophy 
iv. Aniridia 
v. Penetrating keratoplasty 
vi. Epithelial downgrowth 
vii. Fibrous ingrowth 
viii. Flat anterior chamber 
2. Posterior pushing mechanisms 
i. Ciliary block glaucoma 
ii. Cysts of the iris and ciliary body 
iii. Intraocular tumours 
iv. Nanophthalmos 
v. Suprachoroidal haemorrhage 
vi. Intravitreal air injection 
vii. Ciliochoroidal effusions 
viii. Scleral buckling procedure 
ix. Retrolental fibroplasia 
II. Open-angle glaucoma 
A. Primary open-angle glaucoma 
1. IOP higher than normal range 
2. IOP within normal range (Normal-tension glaucoma) 
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B. Secondary open-angle glaucoma 
1. Pigmentary glaucoma 
2. Pseudoexfoliation glaucoma 
3. Steriod induced glaucoma 
4. Lens-induced glaucoma 
i. Phacolytic 
ii. Lens-particle glaucoma 
iii. Phacoanaphylaxis 
5. Glaucoma after cataract surgery 
i. α-chymotrypsin glaucoma 
ii. Glaucoma with viscoelastics 
iii. Pigment dispersion and intraocular lens induced 
iv. UGH syndrome 
v. Glaucoma post Nd-YAG laser posterior capsulotomy 
vi. Glaucoma with vitreous in anterior chamber 
6. Glaucoma after trauma 
i. Chemical burns 
ii. Electric shock 
iii. Radiation 
iv. Penetrating injury 
v. Contusion injury 
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7. Glaucoma associated with intraocular haemorrhage 
i. Ghost cell glaucoma 
ii. Haemolytic glaucoma 
iii. Haemosiderosis 
8. Glaucoma associated with Retinal detachment 
9. Glaucoma after vitrectomy 
i. Intraocular gas 
ii. Intraocular silicone oil 
10. Glaucoma with uveitis 
i. Fuchs heterochromic iridocyclitis 
ii. Glaucomatocyclitic crisis 
iii. Trabeculitis 
iv. Herpes simplex 
v. Herpes zoster 
Primary Open Angle Glaucoma 
Primary open angle glaucoma is a chronic progressive optic 
neuropathy with characteristic pattern of optic nerve damage and 
corresponding visual field loss which develops in the presence of open 
anterior chamber angles. It manifests by cupping and atrophy of the optic 
disc in the absence of other obvious causative ocular or systemic 
conditions known to cause glaucomatous disease. Elevated IOP is an 
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important risk factor for POAG along with other risk factors such as 
lower ocular perfusion pressure, race, low central corneal thickness, 
advanced age and positive family history. 
The major theories for optic disc damage in POAG are –  
1. Onset of vascular dysfunction causing ischemia to the optic nerve 
2. Mechanical dysfunction via compression of the axons within 
lamina cribrosa 
The cause of raised IOP in POAG is due to the resistance to aqueous 
outflow –suggested by multiple theories like 
1. Trabecular meshwork by accumulated material. 
2. Loss of trabecular endothelial cells. 
3. Reduction in pore density and size in the inner wall of 
endothelium of Schlemm’s canal. 
4. Loss of giant vacuoles in the inner wall endothelium of the 
Schlemm’s canal. 
5. Loss of normal phagocytic activity. 
6. Disturbance of neurologic feedback mechanism. 
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Pseudoexfoliation glaucoma 
Pseudoexfoliation syndrome is characterised by slit-lamp 
visualization of white powdery fibrillar material (PXF material) in the 
anterior segment of the eye. Mutations in the LOXLl, seem to be present 
in nearly all cases of exfoliation syndrome and exfoliation glaucoma. 
Histologically, this material has been found in and on the lens epithelium 
and capsule, pupillary margin, ciliary epithelium, iris pigment epithelium, 
iris stroma, iris blood vessels, and subconjunctival tissue.  
The chamber angle is often characterized by a trabecular meshwork 
that is heavily pigmented with brown pigment, usually in a variegated 
fashion along with an inferior pigmented deposition, scalloped in nature, 
present anterior to the Schwalbe line called the Sampaolesi line.  
The mechanism by which pseudoexfoliation causes glaucoma is 
congestion of the trabecular meshwork by the fibrillar material causing 
Open angle glaucoma and the zonular laxity causing angle closure 
glaucoma. The mean IOP is also higher in affected PXF glaucoma 
individuals compared with primary open angle glaucoma patients with 
IOPs that also fluctuate more widely. Those individuals who have 
glaucoma at the time of diagnosis often not only have higher pressures, 
but also have more severe optic nerve damage compared to POAG. 
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Management of Glaucoma 
The visual impairment caused by Glaucoma is irreversible and the 
loss of peripheral vision, depth perception and contrast sensitivity has a 
major effect on an individual’s life. The treatment goals, according to 
AAO practice guidelines, include achieving a stable optic nerve or retinal 
nerve fibre layer status, controlled IOP and stable visual fields while 
maintaining quality of life. (15) The only way currently available and 
proven to slow or stop progressive glaucomatous damage is reducing the 
intraocular pressure below the level at which further damage to the optic 
nerve does not take place. Achieving this “target-pressure” is dependent 
on the patient - based on initial IOP, severity of damage, age, compliance 
and reasonable expectations. This needs to be continually reassessed and 
reset based on the clinical course.  
The currently available modalities in attaining this target-IOP 
include medical therapy, laser trabeculoplasty, surgical options and 
cyclodestructive procedures. While multiple large-scale randomised 
studies have shown local treatment – either medical or surgical – lowers 
the intraocular pressure and prevents further visual field loss to a 
statistically significant extent in POAG, and OHT, the available evidence 
does not suggest which modality to be used as the first choice or when 
18 
 
should a patient who has been medically treated undergo surgery. 
(17,42,44) 
Most clinicians begin with medical therapy, then go on to laser 
surgery, and finally perform incisional surgery if the IOP is not 
adequately controlled. This stepwise process reflects the safety and 
efficacy of the treatments for the individual patient.  
Conversely several clinical trials have studied using laser first or 
incisional surgery first and have obtained comparable results to primary 
medical therapy. (16,17,55) 
Medical therapy – Antiglaucoma agents  
The mainstay of treatment of over a century, owing to its safety, 
reliability and simplicity, majority of patients respond well to topical 
Antiglaucoma agents. More over being relatively cheaper and without the 
obvious risks associated with surgery, most patients prefer medical 
management initially. The Collaborative Normal tension Glaucoma Study 
(CNTGS) and the Early Manifest Glaucoma Trial both showed that 
reducing intraocular pressure had a positive effect by reducing the risk of 
visual field progression in open angle glaucoma. The Collaborative 
Glaucoma Initial Therapy Trial at the end of 5 years showed no 
difference in the progression of visual field loss with medical or surgical 
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management. Though the quality of life was equal in both groups, the 
local side-effects were more among the medically treated while the 
incidence of cataract and reduced visual acuity more following surgery. 
(12,14) 
As explained in-detail in subsequent sections, due to the 
inflammatory reaction induced by long term topical therapy, medically 
treated eyes may not have as good a success rate following filtering 
surgery when compared to eyes treated with primary surgery.(21,22,56) 
Other problems associated with topical medical management were the 
possible local and systemic side-effects. Lastly there is the issue of 
compliance which is extremely important especially in a chronic disease 
condition like glaucoma. 
Topical Antiglaucoma agents can be divided into 5 classes 
1. Adrenergic receptor antagonists 
 Timolol, Betaxolol, Levobunolol, Carteolol, Metoprolol 
2. Adrenergic agonistis 
 Non Selective – Epinephrine, Dipivefrine 
3. Cholinergic agents 
 Direct acting – Pilocarpine 
 Indirect acting – Echothiophate iodide, Demecurium 
bromide, Physostigmine, Neostigmine 
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4. Prostaglandin analogues 
 Latanorpost, Bimatoprost, Travoprost, Unoprostone, 
Tafluprost 
5. Carbonic anhydrase inhibitors 
 Dorzolamide, Brinzolamide 
Cholinergic agents 
The first Antiglaucoma medication to be introduced was the 
calabar bean which turned out to be the original source for 
Physostigmine, a potent miotic. The IOP lowering effects and ability to 
break angle closure attacks were not appreciated till later in 1876 when it 
was reported by Laqueur and Weber independently. Weber was also the 
reason behind Pilocarpine, the second miotic, which still holds a place as 
an adjunctive therapy even a century since its introduction.  
Mechanism of action  
 Open angle glaucoma - acts on the muscarinic receptors in the 
smooth muscles and causes contraction of the ciliary muscle which 
produces traction on the scleral spur and displaces it posteriorly. 
This in turn causes further traction on the trabecular meshwork 
resulting in separation of the trabecular sheets and prevents the 
Schlemms canal from collapsing. Thus increasing aqueous outflow 
in open angle glaucoma. 
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 Angle closure glaucoma – Pilocarpine causes pupillary constriction 
by stimulating the muscarinic receptors on the iris sphincter. This 
pulls the iris root away from the angle and improves outflow in 
angle closure. 
Uses 
 Angle Closure glaucoma – to treat acute angle closure attack and 
facilitate laser iridotomy 
 Peripheral iridotomy - to achieve miosis prior to laser iridotomy 
 Plateau iris – to prevent synechial angle closure. 
Side-effects 
 Functional - Brow ache, Induced myopia, Punctal stenosis, Miosis 
leading to diminished vision and constricted fields 
 Anatomical - Conjunctival congestion, Cataract, Rhegmatogenous 
Retinal detachment, Increased blood aqueous barrier permeability  
Contraindications 
 Active anterior uveitis 
 Rubeosis iridis 
 Extensive angle closure with very less conventional outflow– 
Pilocarpine can paradoxically elevate IOP by reducing the 
uveoscleral outflow 
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 High myopia 
 History of retinal detachment 
 Peripheral retinal degeneration 
Adrenergic agonists 
Epinephrine was introduced in 1901 when Jean Darrier first 
discovered its IOP lowering property and first described its role as an 
adjunct along with Pilocarpine as an Antiglaucoma medication.  
The non-selective adrenergic agonists like Epinephrine and 
Dipevefrin act by reducing the aqueous production as well as by 
increasing both the conventional and uveo-scleral outflow. Although 
effective the non-selective adrenergic agonists have been largely replaced 
by selective alpha receptor agonists like Brimonidine, Apraclonidine and 
Clonidine.  
Mechanism of action  
 Reduces aqueous production  
 Reduces episcleral venous pressure (Clonidine) 
 Increased outflow facility 
 Increased uveoscleral outflow (Brimonidine) 
 Neuroprotection (Brimonidine) 
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Uses - Long term management of Open angle glaucoma and ocular 
hypertension 
Side-effects 
 Allergic conjunctivitis (Brimonidine) 
 Dry mouth 
 Somnolence 
Contraindications – children and infants – Can cause CNS depression 
with risk of bradycardia, hypotension, seizures and apnoea.(67-68) 
Carbonic anhydrase inhibitor 
Acetazolamide first appeared in early 1950s and by 1954 its potent 
IOP lowering effect was known. However it had a number of unpleasant 
side effects and the topical formulation had little to no effect on IOP. The 
search for topical carbonic anhydrase inhibitors was nearly abandoned till 
Dorzolamide was marketed in 1995 by Merck Research Laboratories as a 
potent and safe Antiglaucoma agent. The second topical CAI was named 
Brinzolamide and marketed by Alcon Laboratories after FDA approval. 
Mechanism of action – lower intraocular pressure by decreasing aqueous 
production by inhibiting carbonic anhydrase II isoenzyme in the ciliary 
epithelium 
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Indications – mainly as second line and adjunctive therapy due to thrice 
daily dosing and modest IOP reduction. 
Side-effects 
 Minimal irritation, transient blurred vision  
 Metallic taste 
 Periorbital dermatitis and allergic conjunctivitis 
 Can worsen endothelial damage in decompensated corneas 
 Transient myopia 
Contraindication – Relative – pregnancy and lactation.  
Beta blockers 
1967 saw the introduction of Propranolol as the first beta blocker 
which was found to lower IOP after intravenous administration. The 
topical agent failed to gain popularity due to its adverse local side-effects. 
It was not till Timolol came in 1976 and the less effective but safer 
Betaxolol was approved in the 1980s that betablockers became the 
leading Antiglaucoma agents and revolutionized glaucoma pharmacology 
becoming the first line agents till it was finally dethroned by 
prostaglandins. However they still remain in common use as an 
adjunctive therapy owing to its efficacy, few ocular side-effects and cost. 
The main drawbacks however are the systemic side-effects. 
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Classification 
 Non-Selective beta-blockers – Timolol maleate, Carteolol, 
Levobunolol 
 Selective beta-blockers - Betaxolol 
Mechanism of action – supresses aqueous humour formation by 30-50% 
by inhibiting adenylate cyclase 
Side-effects 
 Ocular – Tear film abnormalities, punctate epithelial erosions, 
allergic conjunctivitis  
 Systemic 
o CVS – bradycardia, hypotension, heart failure 
o RS – bronchospasm, aggravating asthma, emphysema, 
bronchitis 
o CNS – sleep disorders, depression, rarely hallucination 
Contraindications – Asthma, Chronic obstructive pulmonary disorder, 
sinus bradycardia and heart block 
Prostaglandin analogues 
The safest and most effective glaucoma drugs till date, this class of 
drugs changed the landscape of glaucoma pharmacology unlike no other 
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and quickly replaced beta-blockers as the first-line agent in glaucoma. 
While the prototype molecule latanoprost was developed at Columbia 
University as early as 1982, it took until 1996 to achieve an approvable 
formulation (Xalatan™, acquired by Pfizer from Pharmacia). Over the 
next decade additional prostaglandin analogues started emerging such as 
Alcon’s Travoprost (Travatan™), Allergan’s Bimatoprost (Lumigan™) 
and Merck’s Taflurprost 
Mechanism of action  
Many studies have shown that prostaglandin analogues not only 
increase outflow facility by increasing uveoscleral pathway functionally 
but also by altering it structurally. (57) Prostaglandin analogues have 
been shown to produce extracellular matrix remodelling, widening of the 
intermuscular spaces along the longitudinal ciliary muscle and dissolution 
of collagen types I and III. (58) Latanoprost was shown to increase matrix 
metalloproteinase 1 activity in the non-pigmented epithelium of the cilary 
body which may account for the loss of extracellular matrix in the uveal 
tract and thus the increased uveoscleral outflow. (59) 
Latanoprost 0.005% currently has become one of the most useful 
antiglaucoma agents due to its potency, single daily dosing and better 
safety profile. 
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Latanoprost is rapidly converted by the cornea into its acidic form 
which seems to be the active ingredient thus making latanoprost the pro-
drug. It reaches maximum concentration in the aqueous humor 1-2 hours 
after instillation and has a half-life of 2-3 hours. In the blood stream, it 
reaches peak concentration in 5 minutes and has a half-life of 17 minutes.  
Compared to timolol, which requires twice daily dosing and is less 
efficacious at night, once-a-day evening dose latanoprost was found to be 
more effective at lowering IOP. It persisted over 24 hours thus effectively 
flattening the diurnal curve and be efficacious throughout the night. There 
was however, a higher incidence of conjunctival hyperaemia but unlike 
timolol there was no incidence of any systemic side-effects like 
bradycardia or hypotension in patients on Latanoprost.(60) Latanoprost 
was also shown to have the best IOP-lowering effect, least systemic side-
effects and very few significant local side-effects as compared to timolol, 
betaxolol and brimonidine. Waldock et has also shown that in patients 
with significant steroid dependent asthma, latanoprost had no adverse 
effect on the respiratory system. (61)  
In patients with normal tension glaucoma, Latanoprost 0.005% was 
found to be the most potent ocular hypotensive agent when compared to 
β-blockers, α agonists and carbonic anhydrase inhibitors. (62) 
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Latanoprost was also shown to be effective in pigmentary 
glaucoma and steroid induced glaucoma. (63,64). 
Other currently available PG analogues include Bimatoprost and 
Travoprost. Bimatoprost in some studies seem to show a slightly better 
IOP lowering effect as compared with Latanoprost and Travoprost thus 
also making it the most cost-effective in reaching target IOP. It was 
however associated with a higher incidence of local side-effects when 
compared to latanoprost. (65–68) 
Travoprost, when compared with Timolol have shown to have 
similar IOP lowering over a 24 hour period but had greater duration of 
action of upto 40hours from a single dose. (69,70) 
Unlike latanoprost, travoprost is more effective when used twice 
daily compared to once daily. However the proportional increase in side-
effects limits its twice daily use. (71) 
Side-effects associated with pg analogues: 
Conjunctival hyperemia – prostaglandins are autocoids which 
cause vascular changes like vasoconstriction, vasodilatation and increased 
vascular permeability. The mechanism is possibly due to release of Nitric 
oxide. Conjunctival hyperemia was less associated with latanoprost (5-
15%) than travoprost (35-50%) and bimatoprost (5-45%). As the 
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hyperemia is mostly minimal and reduces with time, discontinuing the 
drug of successful treatment in view of the hyperemia is not 
recommended. (72,73) 
Eyelash Changes – hypertrichosis is well documented sideffect of 
prostaglandin analogue. Misdirected growth resulting in lash ptosis or 
trichiasis needing management has also been reported in some cases. This 
effect is also being studied among dermatologists for the treatment of 
alopecia. (74,75) 
Induced iris darkening – an irreversible side-effect of all PGF2 
alpha analogues, develops in the first year of treatment. The 2 possible 
mechanisms of induced iris darkening are an increase in iris stromal 
melanocyte numbers and increase melanogenesis or migration of iris 
stromal melanocytes to thicken the anterior border region. Incidence of 
iris hyperpigmentation after 6-12 months of therapy varies between 1-3% 
with travoprost, 5-10% with latanoprost and 1.1-1.5% with bimatoprost. 
(76–78) 
Iris cysts – few cases have been reported with the use of 
latanoprost causing pigmented epithelial cyst formation possibly due to 
flow pressures caused by increased uveosleral drainage. Withdrawal of 
the drug is also shown to cause reversal of the cysts without any 
recurrence. (79) 
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Periocular skin pigmentation – long term topical PG analogues 
have been associated with darkening of the skin of the lids or other sites 
around the eyes. The mechanism, though still unclear, is possibly due to 
the prostanoid effects on melanogenesis and melanin production. In case 
of bimatoprost, it is due to contact dermatitis. The change however is 
reversible unlike the iris hyperpigmentation. (80–83) 
Breakdown of the blood-aqueous barrier – due to PG analogue use 
has been linked to recurrence of uveitis in susceptible individuals and 
cystoid macular edema especially when there is a coexisting disruption of 
the posterior lens capsule which allows the inflammatory mediators to 
reach the macula especially after cataract extraction or even YAG 
capsulotomy. (84,85) 
Reactivation of Herpes simplex keratitis – occasional cases of 
reactivation of latent herpes keratitis have been reported following the use 
of Pg analogues in the form of dendrites, pseudodendrites and 
keratouveitis. (86) 
Surgical management 
When compared to medical therapy, surgical management is more 
likely to control IOP and maintain it for a longer duration. Though the 
visual function may be better preserved, the visual acuity may be affected 
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earlier as compared to medical management due to cataract formation. 
(87) Being less dependent on medications, the quality of life may be 
better and the factor of compliance is not much of significant concern. 
Moreover in the long run, provided there are no complications and the 
benefits remain, the cost of a one-time surgery may be less than the cost 
of using topical medications. (88,89) 
However being an irreversible treatment option with a significant 
risk of complication and adverse sequelae, it is understandable why trial 
with primary medical management is generally preferred over primary 
surgery 
Trabeculectomy  
Modern trabeculectomy, popularised by Cairns in the 1960s 
quickly replaced the full-thickness surgery due to lesser complications 
and better success rates which improved even further with 
antimetabolites, collagen implants, releasable sutures, laser-suture-lysis 
and Anti-VEGFs. (90) 
Trabeculectomy, a partial-thickness filtration surgery, is currently 
the first choice for medically intractable glaucoma. Surgery is generally 
indicated when there is no internal flow block and IOP remains too high 
despite maximally tolerated medical therapy. The success rate of modern 
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trabeculectomy in experienced hands is estimated between 60 and 100%, 
depending on patient selection, definition of success and length of follow-
up. (91) 
Cataract and Glaucoma  
Glaucoma being a disease of the elderly often coexists with 
cataract and each condition can influence management of the other. In 
developing countries, glaucoma is often detected at an advanced stage 
when the patient presents with cataract. In areas with poor health care and 
accessibility, patients can present late with phacolytic or phacomorphic 
glaucoma. Progressive lens change can mimic the functional changes 
seen in glaucoma such as visual field loss and reduced visual acuity, the 
anatomical changes such as narrow angles and hinder optic disc 
visualization making diagnosis difficult. Alternatively long term 
Antiglaucoma medications (eg. anticholinesterases) or even prior 
glaucoma surgery can accelerate cataract formation. (92) 
Hence the importance of considering both these diseases while planning 
the treatment of one. 
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While considering patients with glaucoma and visually significant 
cataract there are 3 choices 
1. Cataract surgery first and tackle the glaucoma aspect later. 
2. Glaucoma filtering surgery first and tackle the cataract aspect 
later after full healing. 
3. A combined procedure with cataract extraction, IOL 
implantation along with a filtration surgery in one sitting. 
Cataract surgery alone causes a long term pressure reduction of 2-4 
mmHg which may be acceptable in a patient with minimal disc and field 
change and well controlled IOP on minimal medical therapy. However it 
is not sufficient for adequate IOP control in all cases thus requiring same 
or increased medical management after 1 year in a great majority of 
patients. (93,94) 
In the presence of early cataract and medically refractory 
glaucoma, a good filtration procedure is a good choice. However the 
effect the subsequent cataract surgery has on the prior successful filtering 
surgery needs to be addressed. Most studies have shown that pre-existing 
filtering surgery can get compromised due to the subsequent cataract 
extraction with a bleb failure rate up to 30-40% possible due to the 
inflammation following the IOL surgery. Even temporally performed 
phacoemulsification has been reported to cause some adverse effect on 
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the pre-existing glaucoma control such as postoperative increased IOP, 
need for antiglaucoma medications or changes in bleb morphology. Thus 
it is possible to lose some IOP control from a prior filtering surgery if a 
cataract surgery is performed at a later date. (95–97) 
The advantages of a combined surgery are as follows 
1. Better long term IOP control than cataract surgery alone. 
2. Surgery performed in a single sitting. 
3. Excellent visual acuity following the surgery in a majority of 
the patients (in absence of retinal pathology) 
Studies comparing ECCE + IOL + trabeculectomy with 
phacoemulsification + IOL + trabeculectomy, have shown the latter to be 
superior in most cases with reliable results such as better visual acuity, 
lower IOPs with fewer medications, fewer postop complications and 
morphologically better looking blebs. This was attributed to the smaller 
incisions needed for surgery. (59,97–100) 
Addition of antimetabolites like MMC to Phacoemulsification + 
IOL + trabeculectomy have improved the outcomes of surgery even 
further with consistently low IOPs, good visual outcomes, large and 
functional blebs.  
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• Glaucoma filtering surgery
• Release of plasma proteins and blood
• Formation of fibrin-fibronectin clot
• Replication and immigration of macrophages fibroblasts
• Formation of fibrovascular granulation
• Continued collagen synthesis, capillary resorption, 
disappearance of fibroblasts
• Dense collagenous subconjunctival scar
Characteristics of A filtering bleb 
The appearance of filtering bleb is an important factor in 
evaluating the outcome of glaucoma filtering surgery. (101)Successful 
outcome can be anticipated when there is minimal engorgement of 
conjunctival vessel during first week. By second and third week, bleb 
becomes more localized and by the end of first month, a well-established 
and moderately diffuse bleb is formed. The bleb will become gradually 
less hyperemic, well established with microcystic vesicles on 
conjunctival surface in around three months. Bleb failure or 
subconjunctival fibrosis is the most common cause of filtering surgery 
failure.  
Wound healing after Glaucoma surgery 
The series of events from surgical trauma to formation of mature scar are 
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The surgically fashioned fistula between the anterior chamber and 
the sub-conjunctival space may fail to drain the aqueous humor 
successfully because of  
 Closure of the fistula with granulation tissue in the immediate post-
op period 
 Encapsulated bleb or Tenon’s capsule cyst which forms a thick 
walled cavity around the loculated aqueous preventing drainage 
during the first few weeks after surgery. 
 Sub-conjunctival fibrosis and flattening of the bleb months or years 
after filtering surgery 
Complications of filtering surgery 
Intraoperative complications 
1. Button holing of the conjunctiva – avoided by meticulous handling 
and use of non-toothed forceps. It is more common with re-surgery 
and presence of adhesions. They are difficult to manage and can result 
in hypotony, shallow anterior chamber or scarring of the bleb. Direct 
repair can be done using purse-string suture or mattress sutures using 
10-0 Nylon. If repair is not possible, a new surgical can site can be 
chosen. 
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2. Flap-related complications – flap tears, premature entries and 
amputations can occur if the scleral dissection is done in the incorrect 
plane. This is more common in buphthalmic or myopic eyes thus 
requiring extra care in these conditions. Flap tears can be managed by 
suturing to the anterior limbal tissue and taking a new flap in a deeper 
plane. Total flap amputations however may need donor scleral flaps. 
3. Hemorrhage – can occur subconjunctivally or from sclera during 
dissection which can affect visualization and can predispose to bleb 
failure. Hyphema can occur during iridectomy which may need 
drainage via paracentesis if large. Suprachoroidal haemorrhage though 
rare is a dreaded complication of filtering surgery and especially 
associated with higher preoperative IOPs, longer axial length and in 
patients with higher episcleral venous pressure. The risks are also 
significantly higher among aphakics, vitrectomised eyes, patients with 
congenital glaucoma and those who are on anticoagulants. This can be 
prevented in the high-risk groups by using pre-op hyperosmotic agents 
to reduce the IOP or releasing the aqueous gradually via paracentesis. 
If suspected, the flap should be immediately closed and sclerotomies 
performed in select cases after 2-3 weeks to drain the fluid. 
4. Expulsive haemorrhage – due to sudden lowering of intraocular 
pressure leading to bleeding from suprachoroidal vessels. Prevented 
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by adequate lowering of IOP prior to surgery and controlled 
decompression of the globe intraoperatively via paracentesis. 
Early Postoperative complications 
1. High IOP and Deep chamber can be due to obstructed flow at the 
sclerotomy site due to tight sutures which can be released or lysed 
using laser or blood/fibrin/iris/vitreous plugging the ostium the latter 
two requiring intervention. Persistently flat bleb with a raised IOP can 
be due to scarring at the episceral surface which can be managed using 
subconjunctival injections of 5FU with or without needling. 
2. High IOP with a shallow chamber can be due to pupillary block 
resulting in iris bombe or aqueous misdirection. Aqueous misdirection 
or malignant glaucoma can be managed medically by cycloplegics and 
aqueous suppressants. No response to medical treatment indicates 
need for intervention by disrupting the anterior hyaloid face using Nd-
YAG laser or pars plana vitrectomy. 
3. Delayed Suprachoroidal haemorrhage characterised by sudden onset 
pain, nausea and loss of vision. Clinical features include, flat AC, loss 
of red reflex and dome shaped choroidal elevations. USG- B scan can 
demonstrate blood in the suprachoroidal space. Management of small 
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haemorrhages can be conservative with topical and systemic steroids 
while larger ones require drainage. 
4. Wound leaks should be thought of if there is hypotony without a 
visible bleb and localised with the Seidel’s test. If antimetabolites 
were used intraoperatively even small leaks may need surgical closure 
else conservative treatment with patching, aqueous suppressants, 
cycloplegics and topical antibiotics like gentamycin or tobramycin 
(known to induce scarring) may suffice especially if the leak is small 
with a well-formed bleb and anterior chamber. 
5. Choroidal detachment is usually caused by hypotony. A vicious cycle 
can set in as the detachments further reduce aqueous flow. 
Management is mostly conservative with topical steroid and 
cycloplegics. Choroidal drainage is indicated only in kissing choroids 
and refractory choroidal detachment. 
Late postop complication  
1. Chronic hypotony is said to occur if the hypotony lasts for more than 3 
months and is associated with drop in visual acuity and hypotony 
maculopathy characterised by choroidal folds with retinal striae 
without edema. Risk factors being young age and myopia. Treatment 
options that can be attempted prior to surgical revision with scleral 
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patch graft include soft contact lenes, cryotherapy to reduce bleb size, 
autologous blood injection and argon laser to the bleb. 
2. Bleb leak usually seen in thin walled blebs following anti-metabolite 
application during surgery. Detected using Seidels test, if present, 
these can be managed with aqueous suppressants, antibiotics, patching 
or soft contact lenses. Risk of endophthalmitis warrants the need for 
careful monitoring of these cases. Leaks that do not respond to 
conservative management and large leaks need alternative options like 
– cyanoacrylate glue, fibrin tissue glue, autologous blood injection and 
surgical revision. 
3. Failed or failing bleb – mainly attributed to subconjunctival fibrosis. 
Formation of an encapsulated bleb prevents filtration of aqueous out 
of the bleb. Bleb failure can be addressed by needling with 
antimetabolite injection. Repeat surgery may be needed when other 
measures fail. 
4. Bleb related infections, blebitis and Endophthalmitis – common risk 
factors are thin-walled blebs seen with antimetabolite use, hypotony, 
leaking bleb, diabetes and inferior limbal blebs. Onset of infection can 
range from few days to up to 20 years following filtration surgery. 
Topical as well as systemic antibiotics are needed along with 
intravitreal injections in case of endophthalmitis. 
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REVIEW OF LITERATURE 
The first line therapy for glaucoma continues to be Antiglaucoma 
medications and there is a high possibility that most individuals with 
glaucoma will be treated for prolonged periods of time with topical 
agents. It is thus necessary to assess the effect of these medications on the 
external and internal structures of the eye and what that translates to in 
subsequent filtration surgery. 
Since conjunctival scarring was known to be the most common 
cause of bleb failure following trabeculectomy and patients who 
underwent early filtration surgery had better surgical outcomes when 
compared with those who were previously on topical medications, many 
ophthalmologists believed the local side effects of the drugs to be a 
causative factor. (21–23) Studies have been carried out since way back in 
1989, in order to determine the local side-effects of Antiglaucoma 
medications. Sherwood et al conducted conjunctival and tenons capsule 
biopsies in 2 patient groups; one which underwent primary surgery for 
glaucoma and the other which received at least two types of topical 
Antiglaucoma medication for a minimum period of 1 year prior to 
surgery. They found a significant decrease in the number of goblet cells , 
increase in hyaline bodies and nonepithelial cells in the epithelium, an 
increase in macrophages, fibroblasts and mast cells in the substantia 
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propria and tenons capsule of multi-treatment group compared to the 
primary surgery group. This suggested that exhaustive medical therapy 
prior to surgery increases the number of tissue inflammatory cells and 
thus enhance the risk of external bleb scarring post filtration surgery. The 
limitations however were that the number of patients included in the 
study were far too low to note any differences among the different types 
of Antiglaucoma agents(22). 
Longstaff et al in 1990 demonstrated that long term topical 
Antiglaucoma medications prior to surgery was a significant risk factor 
for surgical failure.(23) The same year Lavin et al compared the surgical 
outcomes among 2 groups of patients who underwent trabeculectomy - 1 
group with a history of medical treatment for more than a year and the 
other group for less than 8 weeks. This unmasked retrospective clinical 
study provided significant proof that long term topical Antiglaucoma 
medications can adversely affect surgical outcomes. However the 
duration of treatment was not strictly documented.(21) Two years later 
Schwab et al had reported significant foreshortening of the inferior fornix 
secondary to conjunctival fibrosis further suggesting the possibility that 
long term medications increases the risk of surgical failure.(102) 
Broadway et al first published a review article in 1993 on the 
conjunctival changes caused by topical Antiglaucoma medication in 
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which he suggested the conjunctival reaction to follow a spectrum from 
severe clinical disease to total tolerance. (Table 3.1) (56) The 
mechanisms that fall within this spectrum (Table 3.2) are many, with 
pseudopemphigoid being the most severe. Drugs like beta-blockers and 
pilocarpine have been reported to cause pseudopemphigoid though the 
numbers are relatively less. Most patients, he suggested, however only 
fall into the middle of the spectrum with subtle and subclinical clinical 
effects which are more pronounced with topical sympathomimetics and 
miotics compared to betablockers. Long term beta-blockers have been 
shown to cause conjunctival changes like epithelial oedema, reduced 
goblet cells and secretory epithelial cells.  
Table 3.1. Conjunctival changes following topical medications 
Severe Clinical 
Disease 
Mild Clinical 
Disease 
Subclinical effect Total tolerance 
Obvious signs 
and symptoms 
 
Subtle signs and 
symptoms 
No signs/symptoms 
but cellular and 
ultrastructural 
changes 
No signs/symptoms, 
cellular 
/ultrastructural 
changes 
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Table 3.2. The mechanism by which conjunctiva reacts to drugs 
1. Cicatrising conjunctivitis 
2. Anaphylactoid (allergic) acute or chronic conjunctivitis (type I 
hypersensitivity) 
3. Allergic contact conjunctivitis (type IV hypersensitivity) 
4. Non-specific irritative/toxic conjunctivitis (non-immunological 
irritation to factors such as pH, tonicity, contamination) 
5. Specific irritative/toxic conjunctivitis (characterised by the 
formation of lymphoid follicles) 
6. Cumulative/deposition/dyschromia (for example, adrenochrome 
deposition with sympathomimetics) 
7. Microbial imbalance and secondary conjunctivitis (delayed allergic 
response, ? type IV hypersensitivity) 
8. Non-specific irritation (in the absence of clinical signs) 
9. Subclinical cellular and 
10. Ultra-structural changes 
11. Total tolerance 
 
Broadway et al later followed with two papers in 1994 on adverse 
effects of topical Antiglaucoma medications. The first, focused on the 
conjunctival cell profile and the second on the outcome of filtration 
surgery. Subsequently in 1996 he also studied the effect of topical 
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corticosteroid in reversal of the conjunctival changes induced by topical 
antiglaucoma medications. In their first study, which evaluated the 
conjunctival changes induced by Antiglaucoma medications, they found 
irrespective of type of drug, administration of topical medications for 
more than 3 years induced significant changes which were worse with 
multidrug therapy.(103) 
Broadway et al in their subsequent study proved that long term 
topical combination therapy could be significant risk factor for failure of 
filtration surgery. They reported surgical failure being associated with 
changes in all 3 layers of the conjunctiva such as significantly more pale 
cells (P<0.01), macrophages and lymphocytes in the epithelium, 
fibroblasts (P<0.05) and macrophages (P<0.05) in the superficial 
substantia propria; and both macrophages and lymphocytes in the deep 
substantia propria (P<0.01).(19)  
His follow-up study in 1996 on the effect of reversal of 
conjunctival changes was able to show not only a histologically 
significant reduction in conjunctival cellularity but also some 
improvement in the success rate of trabeculectomy when the patients 
were started on a weak topical corticosteroid and asked to discontinue the 
sympathomimetic 1 month prior to surgery. Patients with advanced 
glaucomatous field loss nearing fixation however were and should be 
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exempted from this regimen due to the theoretical risk of rise in 
IOP.(104)  
Hong et al (2006) concluded that long term Antiglaucoma 
medications can alter the conjunctival surface by causing significant 
squamous metaplasia and thus adversely affect the outcome of glaucoma 
surgery. In this study the impression cytology scores according to 
Nelsons method were found to be higher among those on combination 
therapy as compared to single drug therapy though there was no 
significant difference among the different types of Antiglaucoma 
agents.(20,105) 
Ocular surface disease and Glaucoma 
Ocular surface disease is frequently encountered in patients with 
glaucoma especially those on long term topical agents. Fraunfelder et al 
(2006) reported a significantly higher incidence of corneal toxicities 
among patients on Antiglaucoma agents, when compared to those on 
topical aminoglycosides for bacterial keratitis. The pathophysiology was 
possibly through the reduction of tear-film stability.(106) Similar reports 
were also given by Baffa et al who suggested the preservative present in 
most Antiglaucoma medications could be the reason behind these 
changes especially BAK. (107) 
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In a baffling and surprising twist, our literature search also revealed a 
retrospective study by Johnson et al (1994) which suggested that 
preoperative use of topical medications did not influence the outcome of 
glaucoma surgery.(29) Unfortunately the full article was not accessible.  
Prostaglandin analogues 
Conjunctival hyperaemia as a side-effect is reported commonly 
following topical prostaglandin analogue therapy , over twice of that seen 
with timolol.(108) Our literature search revealed a meta analysis by 
Honrubia et al in 2008 and one by Eyawo et al in 2009 both of which 
showed higher incidence of hyperemia following topical Bimatoprost and 
travoprost as compared to Latanoprost.(73,109) Hyperaemia caused by 
prostaglandin analogues is of concern for ophthalmologists as it can lead 
to surgical failure as well as poor compliance due to the poor cosmesis. 
The cosmetic change is also of concern as it was attributed by nearly two-
third of patients in another study by Friedman et al as a cause for non-
compliance to treatment.(110) However there is no proven evidence 
stating that hyperemia alone decreases surgical success rates. 
The incidence of subclinical inflammation is of significant concern 
as the status of the conjunctival and subconjunctival tissue is an important 
factor for surgical success. Guenoun et al who studied the action of 
prostaglandin analogues in vitro conjunctiva-derived cells suggested the 
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toxicity is more induced by the preservative than the medication itself. He 
also found a possible protective effect of prostaglandin analogues against 
BAK toxicity as he found reduced inflammatory markers even with 
higher BAK concentrations.(111) Conversely, Uusitalo et al reported 
HLA-DR expression, marker of inflammation, even among patients using 
preservative free prostaglandin analogues.(112) Furtado et al compared 
the conjunctival expression of HLA-DR, in eyes treated with topical 
prostaglandin analogues versus eyes treated with other drugs and found 
no significant increase in HLA-DR among the group on topical 
prostaglandin analogues. Interestingly in a previous study by the same 
group which studied impression cytology specimens, the expression of 
HLA-DR was higher among patients using prostaglandin analogues even 
without any clinical signs of inflammation which is frequent in early 
stage of treatment. (113,114) Russ et al compared the effects of 
prostaglandin analogues and timolol maleate in the rabbit conjunctiva and 
demonstrated that timolol induced more severe changes as compared to 
prostaglandin analogues which could be the consequence of enhanced 
fibroblast activity. They also reported increased goblet cell count in 
patients treated with prostaglandin analogues, a change not seen with 
timolol.(115) Terai et al who compared the effect of timolol and 
latanoprost on the human conjunctiva found the latanoprost treated group 
to have lesser inflammatory reaction than the timolol group. The study 
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also found an up regulation of CD68 antibodies, an indicator for acute 
and chronic inflammation, among the timolol group and concluded that 
latanoprost therapy might have a more favourable effect on the outcome 
of trabeculectomy. (116) Similar conclusions were also made by Pisella 
et al who compared in vitro and in vivo effects and showed while 
unpreserved formulations were definitely better, preserved latanoprost 
caused less toxicity than preserved timolol.(117)  
Perez-Roca et al (2015) recently studied the effects of 
prostaglandin analogues on primary cultures of human conjunctival 
stromal cells and reported cell damage with all four prostaglandin 
analogues, latanoprost, bimatoprost, travoprost and tafluprost. Among the 
4 formulations, tafluprost was less toxic although they did acknowledge 
the fact that this was the only formulation which did not contain BAK as 
a preservative. (118) The reduced toxicity of preservative free tafluprost 
compared to commercially available Latanoprost preserved with BAK 
was previously reported by Liang et al, back in 2008, on rabbit cornea 
and conjunctiva.(119) 
Benzalkonium chloride  
Used as a preservative in most glaucoma medications, 
Benzalkonium chloride (BAK) had been implicated as one of the major 
causes of conjunctival inflammation in eyes undergoing long term 
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treatment.(120) This quarternary ammonium detergent exerts 
antibacterial activity by causing non selective cytoplasmic membrane 
lysis and protein denaturation making it ideal to prevent bacterial 
contamination of traditionally designed multidose ophthalmic solution 
containers.(120) The down-side however has been the cytotoxic effects 
on the ocular surface which can cause conjunctival metaplasia and tear 
film breakdown.(19,121–123) Badouin C reported 24 out of 26 patients 
receiving treatment with two or more BAK preserved drugs for at least 1 
year had abnormal inflammatory markers, fibroblastic markers or both. 
(124) Thus it wasn’t a surprise when prolonged use of preserved 
antiglaucoma agents was associated with increased risk of early 
trabeculectomy failure owing to the subclinical conjunctival 
inflammation.(19) The PESO Study was able to show a dose response 
curve with respect to the amount of preoperative BAK exposure and 
proved that increased amount of preserved drops used per day increases 
the risk for early qualified failure. With each additional drop containing 
BAK, the study showed an increase in risk of failure by a factor of 1.21 
making BAK the most likely etiological agent behind failure of filtration 
surgery. (125) 
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Alternatives to BAK 
Three new, less toxic preservatives currently available are Purite, a 
stabilized oxychloro complex, Sofzia, a buffer system containing boric 
acid, propylene glycol, sorbitol, and zinc chloride, and Polyquad 
(polyquaternium- 1), a polycationic polymer previously used in personal 
care products and for contact lens care. Studies have shown, 
inflammatory cells and damage scores with purite based formulations to 
be significantly less than formulations containing BAK.(126). Sofzia or 
polyquad have also been shown to be safer than BAK.(127,128).  
 
 
 
  
  
 
 
PART – II 
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MATERIALS AND METHODS 
Objective  
To evaluate the effects of prostaglandin analogues on surgical 
outcomes of glaucoma filtration surgery 
 To determine the effect of topical prostaglandin analogues as 
compared to other antiglaucoma agents on the results of glaucoma 
filtration surgery. 
 To determine the effects of prostaglandin analogues as compared 
with other Antiglaucoma agents on the cell population profile of 
the conjunctiva and to relate any differences to the outcome of 
glaucoma filtration surgery. 
Materials and Methods 
Study setting – Aravind Eye Hospital and PG Institute of 
Ophthalmology, Madurai 
Study design – Cohort study 
Study population – All diagnosed cases of POAG/PXFG undergoing 
Glaucoma triple procedure from Jan 2016 to December 2016 who have 
been on topical Antiglaucoma medications for a minimum period of 3 
months 
Duration of study – I year recruitment and 6 months follow-up 
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Selection criteria – patients >45 years age suffering from glaucoma 
(POAG or PXFG) on topical medications for a minimum of 3 months 
duration undergoing glaucoma triple procedure. 
Exclusion criteria  
 Patients suffering from ocular or systemic inflammatory diseases 
 Patients on long term topical steroid medications 
 Previous history of eye surgeries 
 Secondary glaucoma 
Statistical analysis 
The information collected regarding all the selected cases were 
recorded in a Master Chart in Microsoft Excel sheet. Data analysis was 
done with the help of computer using the software Statistical Package for 
Social Sciences (SPSS Inc., Chicago, IL, version 22.0 for Windows). 
Quantitative variables were expressed as mean and standard 
deviation. Student’s unpaired test was used to test the significance of 
difference between quantitative variables and Yate’s and Fisher’s chi 
square tests for qualitative variables. A 'p' value less than 0.05 denotes 
significant relationship. 
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Sample size calculation 
 The sample size of 116 (58 in each arm) patients was calculated to 
be included in the study to prove the difference of surgical success 
between prostaglandin and non-prostaglandin groups, with assumed 
percentage of surgical success in prostaglandin 50% and in non-
prostaglandin 75%, and 5% level of significance, 80% power. 
Methodology 
After obtaining permission from the institutional ethics committee 
consenting patients were selected based on the inclusion and exclusion 
criteria. 
Informed consent forms were administered to the patients who 
satisfy the inclusion and exclusion criteria prior to the surgery. 
Information was taken as per the proforma preoperatively. Patient 
was evaluated postoperatively for signs of bleb failure and followed up 
for upto 6 months.  
Consenting patients who satisfy the selection criteria were 
subjected to a conjunctival biopsy at the time of surgery. 
A 2mm x 2mm superior bulbar conjunctival biopsy was taken from 
the edge of the conjunctival flap at the time of filtration surgery with 
minimal crush damage and sent for histopathological examination after 
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preserving in formalin. Biopsy specimens were taken from the same 
conjunctival region to reduce the regional differences in cellularity. All 
biopsy specimens were taken before the application of antimetabolites. 
The samples were evaluated by a masked observer, after 
processing and staining, for number of goblet cells, intraepithelial and 
subepithelial lymphocytes, mast cells and plasma cells under light 
microscope. The average of 3 high power fields was taken for cell counts. 
For each specimen, the numbers of goblet cells and lymphocytes were 
counted in the epithelial layer and the numbers of lymphocytes, plasma 
cells and mast cells were counted in the subepithelial layer and substantia 
propria. Cell counting and identification were established by rigid 
criteria. Cells were counted only when both nuclear and cytoplasmic 
morphologic features made clear identification of cell type possible.  
Patients were evaluated during the subsequent follow-up visits and 
categorised based on the success criteria. 
Surgical technique 
A superior fornix-based conjunctival flap was dissected. Using 
gentle bipolar cautery hemostasis was achieved. Mitomycin C (MMC) 
0.4mg/ml was soaked onto 3 fragments of weck-cell sponge and these 
were inserted into the subconjunctival space as posteriorly as possible. 
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After 2 minutes sponges were removed and the area was irrigated with 
20ml balanced salt solution to wash out the residual MMC. A 4 × 4 mm 
triangular or quadrangular scleral flap was dissected upto the clear 
cornea. Phaco was performed via a temporal corneal section and 
intraocular lens inserted. A window opening is created under the flap with 
a Kelly’s punch to remove a portion of the sclera, Schlemm's canal and 
the trabecular meshwork to enter the anterior chamber. The scleral flap 
closure was performed with fixed or releasable 10-0 nylon sutures 
depending upon the surgeon’s judgement. Balanced salt solution was 
irrigated through the paracentesis to ensure filtration. Water tight 
conjunctival suturing was performed with 8-0 vicryl wing sutures. More 
balanced salt solution was irrigated through the paracentesis to form the 
anterior chamber. Intracameral Moxifloxacin 0.1mg was injected, 
atropine 1% drops were applied and eye was patched and shielded. 
Post-operative care and evaluation 
A standard post-operative regimen of topical antibiotic steroid eye 
drops (Gatifloxacin 0.3% w/v with Prednisolone acetate IP 1.0%) for first 
90 days (in tapering doses every week) was followed in both the groups 
along with Homatropine eye drops (2 times a day for 1 month). 
Glaucoma medications for the non-operated eye were continued. 
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Post-operatively, patients of both groups were reviewed on 
· 1st day 
· 15days 
· 1 month 
· 3 months 
· 6 months 
In each visit the parameters assessed were 
· Best corrected visual acuity using Snellen’s Chart at 6 meters 
· IOP using Goldmann Applanation Tonometer (except in Post-
operative day 1) 
· Number of anti-glaucoma medications used 
· Complications and interventions 
Complications were defined as follows- shallow anterior chamber, 
hyphema, choroidal effusion, persistant leakage, hypotony 
(IOP<5mmhg), macular edema, encapsulated bleb, suprachoroidal 
haemorrhage, blebitis and endophthalmitis. 
Releasable suture removal, laser suture-lysis and bleb needling was 
considered as a part of normal post-operative care and therefore not 
considered as a re-surgery or failure. Bleb revision or repeat 
58 
 
trabeculectomy or use of Glaucoma drainage device were considered as 
re-surgery/failure.(129) 
Surgical outcomes according to guidelines given by the World 
Glaucoma Association.(129) 
 Complete success - final recorded IOP <=21 mmHg and >6 mmHg 
without anti glaucoma medications or bleb needling after surgery, 
no postoperative laser treatment (except for YAG capsulotomy or 
argon laser suture lysis) and no further incisional surgery for 
control of IOP.  
 Qualified success - IOP <=21 mmHg and >6 mmHg with one or 
more anti glaucoma medications or bleb needling and no 
postoperative laser treatment (except for YAG capsulotomy or 
argon laser suture lysis) and no further incisional surgery for 
control of IOP.  
 Failure - IOP of more than 21 mmHg or less than 6 mmHg on 2 
consecutive study visits 
 Complete failure - loss of light perception attributable to glaucoma, 
or the necessity for further glaucoma surgical intervention like 
incisional surgery or trans-scleral diode laser treatment to control 
IOP 
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Figure 4.1. Fornix based conjunctival flap 
 
 
 
 
 
 
 
Figure 4.2. Application of MMC sponges 
 
 
 
 
 
 
 
 
60 
 
Figure 4.3. Creation of partial thickness scleral flap 
 
 
 
 
 
 
 
Figure 4.4. Phacoemulsification 
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Figure 4.5. Foldable IOL placed in bag 
 
 
 
 
 
 
 
 
Figure 4.6. Sclerostomy using Kelly’s punch 
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Figure 4.7. Surgical iridectomy 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Closure of scleral flap with 10-0 Nylon sutures 
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Figure 4.9. Conjunctival closure with 8-0 Vicryl sutures 
 
 
 
 
 
 
 
Figure 4.10. Good bleb at Postop day 1 
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Figure 4.11. Good bleb at 2 weeks postop 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Well-functioning bleb at 1 month 
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RESULTS 
 
Over a one year recruitment period from January to December 
2016 a total of 109 eyes of 109 patients were recruited who satisfied the 
inclusion and exclusion criteria. Of the total number recruited, 7 cases 
were lost to follow-up. The rest 102 patients were observed for a 
minimum period of 6 months from date of surgery for signs of bleb 
failure or fibrosis. The results and observations of our study has been 
shown in the following tables and their corresponding graphs.  
 
Demographic details 
Age distribution 
Most patients in our study population (47.7%) were in the 6th and 
7th decade of life. The mean (SD) age of patients in the PG analogue 
group was 62.9 (7.8) years and Non PG analogue group was 65.8 (9.5) 
years which was not statistically significant (p – 0.096).  
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Table 5.1 
Age distribution 
PG Group Non PG Group 
No % No % 
Up to 50 yrs 3 7.1 6 9.0 
51 – 60 yrs 10 23.8 13 19.4 
61 – 70 yrs 25 59.5 27 40.3 
71 – 80 yrs 2 4.8 16 23.9 
Above 80 yrs 2 4.8 5 7.5 
Total 42 100.0 67 100.0 
Range 45 – 81 yrs 45 – 82 yrs 
Mean 62.9 65.8 
SD 7.8 9.5 
‘p’ 0.096 Not Significant 
 
 
Figure 5.1 
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Sex distribution 
Males formed the majority with 62.3%. Among those in the PG 
analogue group 66.7% were males while in the Non PG analogue group 
59.7% were males. No statistically significant co-relation was found. 
(p=0.598). 
Table 5.2 
Sex 
No of Cases in 
PG Group Non PG Group 
No % No % 
Male 28 66.7 40 59.7 
Female 14 33.3 27 40.3 
‘p’ 0.598 Not Significant 
 
Figure 5.2 
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Diagnosis 
Among the total number of cases 87 (79.8%) had Primary open 
angle glaucoma while 22 patients were diagnosed with Pseudoexfoliation 
glaucoma. Among the PG analogue group 81% had POAG while among 
the Non PG analogue group it was 79.1% with POAG. 
Table 5.3 
Diagnosis 
No of Cases in 
PG Group Non PG Group 
No % No % 
POAG 34 81.0 53 79.1 
PXFG 8 19.0 14 20.9 
‘p’ 0.991 Not Significant 
 
Figure 5.3 
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Drug Category 
42 patients were in the PG analogue group while 67 were in the 
Non-PG analogue group. (Table 5.4) Among the PG analogue group 
90.5% were on combination therapy while 50.7% were combination 
therapy in the Non-PG analogue group. 
Table 5.4 
Drug Category 
PG Group Non PG Group 
No % No % 
Single drug PG Analogue 4 9.5 - - 
Single drug Non PG Analogue - - 33 49.3 
Multidrug PG Analogue 38 90.5 - - 
Multidrug Non PG Analogue - - 34 50.7 
Total 42 100.0 67 100.0 
 
Figure 5.4 
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Duration of therapy till surgery 
Mean duration of drug use was higher in the PG analogue group 
46.4 months (SD 42.7months) compared to the Non PG analogue group 
14.2 months (SD 14.1 months) which was statistically significant. 
(p<0.001). 
Table 5.5 
Duration of Drug Use 
PG Group Non PG Group 
No % No % 
< 6 months 8 19.0 28 41.8 
6 – 12 months 7 16.7 16 23.9 
1 – 5 yrs 14 33.3 23 34.3 
Above 5 yrs 13 31.0 - - 
Range 3 – 144 months 2 – 60 months 
Mean 46.4 months 14.2 months 
SD 42.7 months 14.1 months 
‘p’ <0.001 Significant 
 
Figure 5.5 
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Exposure to PG analogue 
Among those in the PG analogue group, the mean exposure to 
prostaglandin analogues was 40.4 months with a SD of 42.3 months. 
Table 5.6 
PG Analogue exposure 
No of Cases in 
PG Group 
No % 
< 6 months 12 28.6 
6 – 12 months 7 16.7 
1 – 5 yrs 11 26.2 
Above 5 yrs 12 28.6 
Total 42 100.0 
Range 0 – 144 months 
Mean 40.4 months 
SD 42.3 months 
 
Figure 5.6 
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Intraocular Pressure 
At pre-operative period, Mean (SD) IOP was 18.1(±7) mmHg in 
PG analogue group and 18.1(4.5) mmHg in Non-PG analogue group 
which was found to be statistically significant (p < 0.001) (Table 5.7). At 
end of 6 months, IOP decreased to 15.0(±5.2) mmHg in PG analogue 
group and 13.3(3.6) mmHg in Non-PG analogue group. Statistically 
significant difference betweent the groups was seen at 1 month (p=0.037) 
and 3 month (p=0.003) follow-ups postoperatively. Final IOP however 
was lower in Non-PG analogue group compared to PG-analogue group 
though without statistical significance (P=0.051) (Table 5.8) 
Table 5.7 
Period 
I O P 
Mean S.D. 
Pre operative 18.11 5.57 
Post Operative 13.88 4.3 
‘p’ < 0.001 Significant 
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Table 5.8 
 
Figure 5.7 
 
 
 
 
 
  
Period 
IOP (mm/Hg) 
‘p’ Significance PG Group Non PG Group 
Mean SD Mean SD 
Pre operative. 18.1 7.0 18.1 4.5 0.983 
Not 
Significant 
2 weeks follow up 16.7 5.6 16.5 5.7 0.88 
Not 
Significant 
1 month follow up 16.7 6.2 14.5 4.6 0.037 Significant 
3 months follow 
up 
16.9 7.7 13.7 4.0 0.007 Significant 
6 months follow 
up 
15.0 5.2 13.3 3.6 0.051 
Not 
Significant 
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Visual acuity 
Table 5.9 shows the results of visual acuity recorded in the pre-
operative visit and on post-operative follow up (2 weeks, 1 month, 3 
months and 6 months) Mean visual acuity between PG group and non PG 
group showed no statistically significant difference in each visit (p>0.05). 
Statistically significant difference was seen between the preoperative and 
postoperative visual acuity as shown in Table 5.10.  
Table 5.9 
Period 
BCVA – Log MAR 
‘p’ Significance PG Group Non PG Group 
Mean SD Mean SD 
Pre-operative. 0.57 0.29 0.6 0.3 0.613 
Not 
Significant 
2 weeks follow 
up 
0.112 0.149 0.149 0.188 0.342 
Not 
Significant 
1 month follow 
up 
0.1 0.138 0.11 0.187 0.755 
Not 
Significant 
3 months follow 
up 
0.086 0.127 0.11 0.193 0.501 
Not 
Significant 
6 months follow 
up 
0.08 0.125 0.1 0.182 0.5 
Not 
Significant 
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Figure 5.8 
 
 
 
 
 
 
 
 
Table 5.10 
Period 
Visual acuity 
Mean S.D. 
Pre-operative 0.71 1.42 
Post-Operative 0.09 0.164 
‘p’ < 0.001 Significant 
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Post-Operative Medications 
Table 5.11 shows the number of postoperative antiglaucoma 
medications needed in both groups for control of Intraocular pressure. No 
statistically significant difference was found, however at 3 month and 6 
months follow-up, patients on the PG analogue group required slightly 
higher number of medications.  
Table 5.11 
Number of 
medications at 
Category 
‘p’ P G NON PG 
Mean S.D. Mean S.D. 
2 weeks 0.048 0.309 0.03 0.172 0.7 Not Significant 
1 month 0.128 0.469 0.179 0.548 0.629 Not Significant 
3 months 0.528 0.941 0.185 0.556 0.051 Not Significant 
6 months 0.694 1.064 0.409 0.803 0.131 Not Significant 
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Final visit medication 
At the final follow up of 102 cases , 23 cases (63.89%) in the PG 
analogue group did not require any additional glaucoma medications, in 5 
cases (13.89%) one anti-glaucoma medication was added to control the 
IOP, 8 cases (22.2%) required 2 or more anti-glaucoma medications to 
control the IOP. In the non PG analogue group 50 cases (75.76%)did not 
require any additional glaucoma medications, in 7 cases (10.61%) one 
anti-glaucoma medication was required to control the IOP and the rest 9 
cases (13.63%) required 2 or more anti-glaucoma agents for IOP control. 
No statistically significant co-relation was found, the number of postop 
medications needed postoperatively was higher for the PG analogue 
group. 
Table 5.12 
 
Number of Antiglaucoma medications 
Category 0 1 2 or more 
 
PG analogue 
23 
 
5 8 36 (35.3%) 
Non PG 
analogue 
50 7 9 66 (64.7%) 
Total 73(71.6%) 12(11.8%) 17(16.7%) 102 
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Complications 
Intraoperative complications encountered included one case of 
PCR with vitreous disturbance during phacoemulsification and one case 
of cheese wiring of the scleral flap during suturing. Both cases were 
managed well and did not have any significant sequelae and therefore not 
included under failure. Bleb needling with 5-FU(5mg/0.1ml) was done in 
9 cases with 5 cases being done at 3 months postop. 5 cases were in PG 
analogue group and 4 cases in non-PG analogue group. There were no 
cases of bleb related infections or endophthalmitis in the study 
population. One patient in the PG analogue group underwent resurgery 
with glaucoma drainage device implantation (AADI) for failed surgery. 
Surgical Outcome 
Table 5.13 shows the surgical outcomes after 6 months among the 
PG and non PG analogue group. Though no statistically significant 
difference was found, the chances of successful filtration surgery were 
higher among the Non PG group compared to the PG analogue group. 
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Table 5.13 
Outcome 
Cases 
PG Group Non PG Group 
No % No % 
Complete Success 21 50.0 48 71.6 
Qualified Success 14 33.3 17 25.4 
Failure 1 2.4 1 1.5 
Complete Failure - - - - 
Lost to follow up 6 14.3 1 1.5 
‘p’ 0.206 Not Significant 
 
Figure 5.9 
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No statistically significant correlation was seen between diagnosis 
or total duration of preoperative medications with outcome as shown in 
Table 5.14 and Table 5.15. 
Table 5.14 
Diagnosis 
Outcome 
Success Failure 
No % No % 
POAG 53 65.4 28 24.6 
PXFG 16 76.2 5 23.8 
‘p’ 0.498 Not Significant 
 
Table 5.15 
Outcome 
Total duration of drugs pre-
operatively(months) 
Mean S.D. 
Complete Success 22.1 28.9 
Qualified Success 36.4 36.0 
Failure 5.5 3.5 
Complete Failure - - 
Lost to follow up 7.7 7.2 
‘P’ 0.095 Not significant 
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Histopathology – Conjunctival Analysis 
Table 5.16 shows the results following histopathological analysis 
of 22 specimens Though there was no statistical significance, the 
numbers of goblet cells and plasma cells were more in the PG analogue 
group while the number of mast cells were more in the non PG analogue 
group suggestive of more subclinical inflammation and fibrosis potential 
in the non PG analogue group. 
Table 5.16 
 
PG. Group Non PG Group  
‘p’ Mean S.D. Mean S.D. 
G.C. 1.63 2.41 0.28 0.4 0.069 Not significant 
IELC 2.22 1.43 3.37 2.81 0.288 Not significant 
SELC 8.75 6.5 8.28 5.8 0.859 Not significant 
Mast Cells 1.72 1.31 1.92 1.46 0.742 Not significant 
Plasma Cells 1.27 2.99 0.03 0.1 0.165 Not significant 
 
Figure 5.10 
 
 
 
 
 
 
0
1
2
3
4
5
6
7
8
9
10
Goblet Cells Intraepithelial
lymphocytes
Subepithelial
Lymphocytes
Mast cells Plasma cells
M
ea
n
Cell type
Histopathology
PG group
Non PG group
82 
 
Figure 5.11. Stroma with increased mast cells and fibrosis 
 
 
 
 
 
 
 
Figure 5.12. Inflammatory epithelium and stroma with increased 
epithelial and subepithelial lymphocytes 
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Figure 5.13. Epidermadised epithelium with reduced goblet cells 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. Fibrotic stroma with increased mast cells  
Inlet showing degranulating mast cell 
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Conjunctival analysis and Surgical outcomes  
Table 5.17 shows the surgical outcomes among the patients who 
underwent conjunctival biopsies. Though no statistically significant 
correlation was found between the cell count and surgical outcome, sub-
epithelial lymphocytes, mast cells and plasma cells were shown to be 
lesser among patients with successful surgical outcomes after 6 months. 
Table 5.17 
 
Outcome 
Success 
Qualified 
success and 
Failure 
Lost to 
follow up ‘p’ 
Mean S.D. Mean S.D. Mean S.D. 
G.C. 1.06 2.27 0.81 1.02 0.44 0.19 
0.865 Not 
significant 
IELC 2.52 1.76 3.71 2.94 1.67 1.86 
0.391 Not 
significant 
SELC 6.57 4.12 12.9 7.69 5.89 2.14 
0.052 Not 
significant 
Mast Cells 1.76 1.14 2.05 1.93 1.56 1.02 
0.862 Not 
significant 
Plasma 
Cells 
0.08 0.29 1.57 3.59 0.33 0.58 
0.321 Not 
significant 
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DISCUSSION 
  The main goal of glaucoma filtration surgery is to achieve a good 
functioning bleb with less complications and adequate reduction in 
intraocular pressure. An ideal bleb should be diffuse, with minimal 
elevation, relatively avascular with conjunctival microcysts. Many factors 
play a role in achieving this outcome. The most important being, the 
wound healing process in the conjunctival tissue which is greatly 
influenced by the degree of subconjunctival inflammation and fibrosis as 
shown in most previous studies. One of the main factors linked with an 
increase in failure rates is use of preoperative medications.  
In our study of 109 eyes of 109 patients, 87 were POAG while the 
rest had pseudoexfoliation glaucoma. Forty two patients had received PG 
analogues prior to surgery while the rest 67 patients were on other 
antiglaucoma agents such as beta-blockers, carbonic anhydrase inhibitors 
and α- adrenergic agonists. 
The pre-operative characteristics were comparable in both the 
groups with respect to the age, sex, pre op IOP and visual acuity. 
With respect to the duration of therapy prior to surgery, PG 
analogue group had a significantly higher mean duration of use compared 
to the non PG analogue group. 
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Post-operative mean visual acuity between PG and Non PG 
analogue group showed no statistically significant difference in each visit 
(P>0.05). In each group, pre-operative and Final follow-up showed 
statistically significant improvement in visual acuity (P<0.001). 
The post-operative IOP reduction was significant at the end point 
in both the groups. The IOP reduction in the PG and Non PG group did 
not show any statistically significant difference in the initial and final 
follow-ups. These however did show a statistically significant difference 
at the 1 month and 3 month visits with PG analogue group recording 
higher IOP reading as compared to the non PG analogue group (p<0.05)  
Intraoperative complications were seen in only 2 cases with one 
case of Posterior capsular rent occurring during phacoemulsification and 
another case of cheese wiring of the scleral flap while suturing. While the 
former had successful surgical outcome, the latter required bleb needling 
postoperatively for bleb fibrosis. 
50% of the PG analogue group and 71.6% of the Non PG analogue 
group had complete success while 33.33% of the PG group and 25.4% of 
the Non PG analogue group had qualified success. Failure was seen in 
only 2 cases with one needing resurgery with glaucoma drainage device 
for IOP control while another had unexplained reduced visual acuity 
postoperatively despite IOP control. Although there was no statistically 
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significant difference between the 2 groups the chance of surgical success 
was slightly higher in the non PG analogue group. 
Previously conducted clinical and experimental studies have 
provided strong evidence that chronic use of antiglaucoma medications 
can induce ocular surface changes resulting in discomfort, inflammation, 
tear film instability and subconjuctival fibrosis which have been shown to 
be directly proportional to the duration of treatment and the type of 
medication used.(103,124,130–132) 
Sherwood et was one of the first to prove this by comparing the 
conjunctiva of patients who underwent primary surgery compared to 
those who were treated with topical medications prior to surgery and was 
able to show beyond doubt that medical therapy prior to surgery increases 
the number of tissue inflammatory cells and thus enhance the risk of 
external bleb scarring post filtration surgery. He showed a significant 
increase in the number of macrophages, lymphocytes, fibroblasts, and 
mast cells in both the substantia propria of the conjunctiva and the 
Tenon's capsule of patients who had received long-term topical 
antiglaucoma medication. The drawback however was the low number of 
samples and that the type of medication used was not taken into 
consideration. Also currently used drugs like beta-blockers or 
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prostaglandin analogues were not available back then and hence this 
study.(22) 
Similar reports were also given by Lavin et al and Longstaff et al 
which noted long term use of topical antiglaucoma medications as a 
significant risk factor for surgical failure.(21,23) 
Our study most closely resembles the series of published literature 
by Broadway et al who studied the antiglaucoma agent induced 
conjunctival changes, outcomes of surgery and effects of reversal of those 
conjunctival changes by topical steroids.(56) However as prostaglandin 
analogues have made their entry to the arsenal only recently, little 
information is available about their influence. Russ et al compared the 
effects of prostaglandin analogues and timolol maleate in the rabbit 
conjunctiva and demonstrated that timolol induced more severe changes 
as compared to prostaglandin analogues which could be the consequence 
of enhanced fibroblast activity. They also reported increased goblet cell 
count in patients treated with prostaglandin analogues, a change not seen 
with timolol.(115,133) Terai et al who compared the effect of timolol and 
latanoprost on the human conjunctiva found the latanoprost treated group 
to have lesser inflammatory reaction than the timolol group. The study 
also found an up regulation of CD68 antibodies, an indicator for acute 
and chronic inflammation, among the timolol group and concluded that 
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latanoprost therapy might have a more favourable effect on the outcome 
of trabeculectomy. (116) Similarly in our study we found an increase in 
goblet cells among the PG analogue group and increase in mast cells in 
the non PG analogue group though there was no statistical significance. 
This is in accordance to other studies by Sherwood et al, Baudouin et al 
and Herreras et which demonstrated that timolol may induce a drop in 
goblet cells and crystallization pattern associated with 
keratoconjunctivitis sicca.(124,134) 
Similar conclusions were also made by Pisella et al who compared 
in vitro and in vivo effects and showed while unpreserved formulations 
were definitely better, preserved latanoprost caused less toxicity than 
preserved timolol and may acutally have a protective effect against the 
toxicity caused by BAK.(117) 
Thus in our study while there was no statistically significant 
difference in surgical outcomes between the 2 groups, the postoperative 
intraocular pressures were found to be higher in the PG analogue group. 
Interestingly the conjunctival biopsies did show higher goblet cell counts 
in the PG group, the subclinical inflammation was found to be higher 
among the Non PG analogue group even though the mean duration of 
treatment was found to be significantly higher in the PG analogue group.  
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Limitations and Recommendations 
The limitations of our study were 
1. Short follow-up period 
2. Involvement of multiple surgeons. 
3. Inclusion of both POAG and Pseudoexfoliation glaucoma which 
could influence the outcome of surgery 
4. No specific preoperative drug protocol. 
5. Effects of preservative used was not taken into consideration 
6. Not a randomised control trial 
7. Significant difference in the duration of medical treatment between 
the 2 groups 
8. Insufficient or inadequate biopsy specimens  
Recommendations 
A single surgeon, randomised control trial with preservative free 
medications, longer follow-up period and standard preoperative regimen 
comparing the different PG analogues will be able to throw further light 
into the outcomes of surgery in these patients. 
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CONCLUSION 
To conclude, in our study, we have found that while different drugs 
and the duration of use do influence the outcome of filtration surgery, 
there is no statistically significant difference in outcomes after 
preoperative use of prostaglandin analogues as compared with other 
agents. In accordance with previous studies, histopathologically, the 
conjunctival changes induced by prostaglandin analogues were more 
favourable to better surgical outcomes as compared with aqueous 
suppressants. The postoperative intraocular pressure reduction 
postoperatively however was found to be lesser and statistically 
significant at 1 and 3 month follow-ups for the Non PG analogue group 
compared to PG analogue group. A randomised controlled trial with 
longer follow-up and lesser confounding factors is necessary to put this 
debate to rest. 
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ABBREVIATIONS 
 
POAG  -  PRIMARY OPEN ANGLE GLAUCOMA 
PACG  -  PRIMARY ANGLE CLOSURE GLAUCOMA 
PXFG  -  PSEUDOEXFOLIATION GLAUCOMA 
IOP   -  INTRA OCULAR PRESSURE 
MMC  -  MITOMYCIN C 
5-FU   -  5-FLUOROURACIL 
AC   -  ANTERIOR CHAMBER 
OHT   -  OCULAR HYPERTENSION 
BCVA  -  BEST CORRECTED VISUAL ACUITY 
SD   -  STANDARD DEVIATION 
MD   - MEAN DEVIATION 
PCR   -  POSTERIOR CAPSULAR RUPTURE 
IOL   -  INTRAOCULAR LENS 
BSS   -  BALANCE SALT SOLUTION 
PG ANALOGUE - PROSTAGLANDIN ANALOGUE 
LSL   -  LASER SUTURE LYSIS 
RSR   -  RELEASABLE SUTURE REMOVAL 
AADI  -  AUROLAB AQUEOUS DRAINAGE DEVICE 
GDD   -  GLAUCOMA DRAINAGE DEVICE 
GC   -  GOBLET CELL 
IELC   -  INTRA - EPITHELIAL LYMPHOCYTES 
SELC  -  SUB-EPITHELIAL LYMPHOCYTES 
MC   -  MAST CELL 
PC   -  PLASMA CELL 
 
 
 
 
CONSENT FORM 
 
Informed Consent form to participate in a clinical trial 
Study Title: Outcome of glaucoma surgery in patients on prostaglandin 
analogues  
Protocol Number:  
Subject’s Name: _______________Subject’s Initials: _____________  
•  Subject ID No: _________________  
• Date of Birth / Age: _________________  
 
 
  Please put initial 
1.  I confirm that I have understood the 
information about the study, procedures and 
treatments for the above study and have had 
the opportunity to ask questions and I have 
received satisfactory answers to all of my 
questions. I have been given a copy of the 
informed consent form to take home. 
[      ] 
2.  I understand that my participation in the study 
is voluntary and that I am free to withdraw at 
any time without giving any reason, without 
my medical care or legal rights being affected. 
However this may not be possible for certain 
surgical procedures. 
[      ] 
 
 
 
 
3.  I understand that the Investigator of the study wants 
to access my health records for research purpose. 
However I understand that my identity will not be 
revealed or information released to third parties or 
published. 
[      ] 
4.  I agree not to restrict the use of any data or results that 
arise from this study provided such a use is only for 
scientific purpose(s) 
[      ] 
5.  I agree to take part in the above study [      ] 
 
Signature (or Thumb impression) of the Subject: 
 _____________________________  
  
 Date: _____/_____/______ 
  
Subject’s Name: 
______________________________________________________ 
  
Signature (or Thumb impression) of Legally Acceptable Representative 
(LAR): 
___________________________________________       Date: 
____________  
Signature of the Investigator: ___________________________Date: 
_____/_____/______ 
  
Investigator’s Name: 
__________________________________________________ 
  
Signature of the Witness ______________________         
Date: _____/_____/_______  
  
Name of the Witness: 
_______________________________________________________ 
 
 
PROFORMA 
 
Outcome of glaucoma surgery in patients on prostaglandin analogues 
 
Study sample Number 
 
EYE –  RIGHT  / LEFT 
Date dd/mm/yy 
      
 
Patient details 
Name 
           
MR No 
           
 
Age________    years        
Gender (M /F)    
History 
Age at diagnosis ________years 
Time since diagnosis _______years _________months  
IOP at first presentation ____________mm Hg 
 
  
    
 
 
Treatment History (current) 
Sl No. Drug Conc. 
Dose 
(drop/ 
day) 
Exposure 
(yrs) 
Preservative 
(with conc.) 
Brand 
       
       
       
 
Treatment history (prior) 
Sl No. Drug Conc. 
Dose 
(drop 
/day) 
Exposure 
(yrs) 
Preservative 
(with conc.) 
Brand 
       
       
       
 
Systemic history (Please tick the appropriate ones) 
DM / HTN / Cardiac / Stroke / Others (please mention below) 
 
Pre-op Ocular Examination 
                Right      Left 
BCVA Distance   
BCVA Near   
 
  
 
 
Anterior Segment 
Lids   
Conjunctiva   
Cornea   
AC   
Iris   
Pupil   
Lens   
IOP   
 
Anterior segment findings suggesting drug intolerance (mention if any) 
 
 
Was topical therapy stopped prior to surgery (YES/NO) If yes mention 
drug and duration since stopped. 
 
 
Fundus 
Media   
Disc     Size 
                 Colour 
                Margin 
                 CDR 
                  NRR 
  
Blood vessels   
Macula   
Others   
 
 
 
CCT   
Axial length   
 
Diagnosis  
Surgery Details 
Type  
Date  
Block used  
Bridle suture (Sup Rectus/ 
Corneal traction) 
 
MMC use (if present/not)  
Postop Medications advised  
 
Intraop Complication Report 
Traction suture related  
Conjunctival Flap 
related 
 
MMC application  
Scleral flap related  
Corneal injury  
Iridectomy related  
Others (Mention if any) 
 
  
 
 
Histopathological Report 
Cell type Number 
Goblet cells  
Intraepithelial Lymphocytes  
Intrastromal lymphocytes  
Mast cells  
Plasma cells  
 
 Follow Up                   DD / MM / YY 
1st Post-op visit  Date  
BCVA   
Applanation tonometry   
Bleb description   
Fundus   
Complications    
Needling/Suture 
lysis/Suture release 
  
 
Antiglaucoma medications 
2nd Post-op visit   Date  
BCVA   
Applanation tonometry   
Bleb description   
Fundus   
Complications    
Needling/Suture 
lysis/Suture release 
  
 
      
      
 
 
Antiglaucoma medications 
3rd Post-op Visit           Date 
BCVA   
Applanation tonometry   
Bleb description   
Fundus   
Complications    
Needling/Suture 
lysis/Suture release 
  
 
Antiglaucoma medications 
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Submitted By: aswin.kmc@gmail.com 
Significance: 1 % 
Sources included in the report: 
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2 
U R K N DU
Study 
no MR No. EYE Age Gender Diagnosis
Medication 
started on Drugs used and Duration
PG 1  
NONPG 2 Category 
Total 
Duration
PG analogue 
exposure
Pre-op 
IOP
Pre-op 
BCVA
Axial 
Length
Date of 
surgery
Complicatio
ns Outcome CCT
LogMAR POD BCVA IOP
Bleb 
description AGM
Secondary 
procedure Date BCVA IOP
Bleb 
description AGM
Secondary 
procedure Date
BCVA 
(logMAR)
(mmH
g)
Bleb 
description AGM
y 
Procedur Date
(logMAR
)
IOP 
(mmHg)
Bleb 
description AGM
Secondary 
Procedure
1 3933991 2 77 1 1 Dec-14 Misopt BDIobrim BD 2 4 24 0 15 0.3 21.63 06-02-2016 0 23-02-16 0.20 17 low bleb none released 29-03-16 0.00 14 bleb+ none Apical LSL 23-03-16 0.48 17 low bleb none 26-04-16 0 12 none 0 1 0.502
2 4103773 2 81 2 1 04-03-2011
Alphagan Z+ Latacom 
15/8/15 1 3 60 6 13 0.3 21.79 13-02-2016 0 01-03-16 0.00 11 bleb+ 0 LSL 12-03-16 0.00 19 bleb+ 0 LSL 28-03-16 0.20 12 bleb+ 0 RSR 13-08-16 0.20 12 low bleb 0 0 1 0.545
3 4136026 1 76 1 2 Aug-15 Britiblu BD 2 2 21 0 22 0.5 22.41 13-02-2016 0 01-03-16 0.60 21 flat bleb none removed + 18-03-16 0.50 18 low bleb removed 01-04-16 0.50 15 low bleb apical LSL 08-07-16 0.5 13 low bleb 0 0 1 0.519
4 4209495 1 65 1 2 01-10-2015 Timoler BD 2 2 3 0 18 1.5 23.1 13-02-2016
iris 
incarcerated 
sideport 19-02-16 0.20 26
vascularised 
bleb
Timole
t BD apical LSL 01-03-16 0.20 26 flat bleb
betabri
m e/d 
BD
bleb needling+ 
iris 
repositioning 12-04-16 0.20 22 low bleb
Betabri
m BD none 12-08-16 0.20 16 low bleb Betabrim BD 0 2 0.541
5 4167765 2 45 2 1 25-11-2015 Misopt e/d 2 2 3 0 28 0 22.72 13-02-2016 0 16-02-16 0.20 14 with 0 0 22-02-16 0.20 14 diffuse 0 0 26-02-16 0.20 11 bleb+ 0 0 01-07-16 0.2 7 vascular bleb 0 0 1 0.584
6 4041103 2 60 1 2 20-05-2015
Combigan BDMonosopt 
BD 2 4 8 0 28 0.6 22.95 20-02-2016 0 05-03-16 0.00 16 low bleb 0
2 RS 
removed 21-03-16 0.00 14
vascualr 
bleb 0 apical LSL 09-04-16 0.00 10 bleb + 0 none 04-11-16 0 16 bleb+ 0 0 1 0.568
7 3995517 1 60 2 2 13-03-2015 Betabrim e/d 2 2 10 0 20 0.5 23.24 20-02-2016 0 04-03-16 0.50 19 flat bleb 0 LSL 04-03-16 0.50 20 0 LSL 24-03-16 0.00 16 flat bleb 0 apical LSL 16-07-16 0 18 low bleb 0 0 1 0.535
8 4114907 1 69 1 2 01-09-2015
Bidin LS1-9-15Monosopt 
Auroprost 8/9/15 1 3 5 5 30 0.5 24.19 23-02-2016 0 09-03-16 0.20 22 bleb+ nasal LSL 23-03-16 0.20 16 low bleb LSL temporal 23-05-16 0.20 13 bleb+ 0 0 20-06-16 0.20 12 bleb+ 0 0 1 0.535
9 3648757 2 58 1 1 28-08-2013 Iotim e/d 2 2 24 0 14 1.07 22.4 25-02-2016 0 25-02-16 0.00 15 low bleb 0 LSL 05-04-16 0.00 16 low bleb 0 LSL 03-05-16 0.20 12 low bleb 0 LSL 31-08-16 0.17 10 low bleb 0 0 1 0.535
10 3659017 2 60 1 1 17-10-2013 Brimolol BD 2 4 24 0 16 0.77 23.52 26-02-2016 0 13-03-16 0.00 16 low bleb 0 LSL 26-03-16 0.00 13 vascularity 0 LSL 27-04-16 0.00 19 0 none 27-07-16 0 13 low bleb 0 0 1 0.519
11 4230215 2 72 1 1 01-01-2015 Timolol BD 2 2 12 0 18 0.3 23.24 01-03-2016 0 16-03-16 0.00 18 bleb+ 0 RS removed 30-03-16 0.20 10 bleb 0 0 11-05-16 0.20 11 bleb+ 0 0 15-07-16 0.2 11 low bleb 0 0 1 0.535
12 4080934 1 65 2 1 13-07-2015
Aurobrim Dorzox 
13/7/15 2 4 8 0 12 0.3 22.76 01-03-2016 0 12-03-16 0.20 11 bleb+ 0 RS removed 21-03-16 0.00 8
iris  at 
ostium 0 04-04-16 0.50 10 bleb+ 0 0 31-01-17 0.3 8 good bleb 0 0 1 0.519
13 4046645 2 63 2 1 24-06-2013 Betabrim Dorzox Bimat 1 3 72 36 19 0.8 22.47 02-03-2016 0 07-03-16 0.30 13 bleb+ 0 LSL 28-03-16 0.30 13 bleb+ 0 LSL 25-03-16 0.30 20 bleb+
Cibrim 
T
Bleb 
needling 11-10-16 0.3 18 fibrosed bleb
Cibrim T 
Dortas e/d 0 2 0.568
14 3297523 2 69 1 1 01-01-2011 Brimolol Dorzox 2 4 60 0 26 0.3 23.24 03-03-2016
PCR vitreous 
disturbance 07-03-16 0.20 18
flat 
vascularised 
bleb 0 LSL 21-03-16 0.20 15
low 
vascularise
d bleb 0 LSL 29-04-16 0.20 16 low bleb 0 LSL 22-08-16 0.20 16 low bleb 0 0 1 0.502
15 4121881 2 52 2 1 11-09-2015 Betabrim Auroprost 1 3 6 6 24 0.8 22.98 04-03-2016 0 18-03-16 0.00 22 bleb+ 0 RSR 04-04-16 0.00 38 bleb m needling 11-04-16 0.00 18 bleb+ m 0 22-12-16 0 12 bleb+ Betabrim 0 2 0.535
16 3354662 2 79 1 1 09-12-2009 Travocom Alphagan Z 1 3 84 84 15 0.2 23.38 05-03-2016 0 11-03-16 0.20 20
vascularised 
bleb
Combi
gan 0 14-03-16 0.50 23 low bleb
Combiga
n RSR 03-05-16 0.50 36
flat 
vascularise
d bleb
an D 
Lumiga
n 0 12-07-16 0.5 22 0
Combigan 
Lumigan 
Misopt 0 2 0.56
17 3059185 1 81 1 1 05-10-2010 Latanoprost Timolet 1 3 72 72 20 0.5 23.32 10-03-2016 0 28-03-16 0.20 12 low bleb 0 0 07-04-16 0.20 12 low bleb 0 0 16-04-16 0.20 14 bleb+ 0 LSL 01-08-16 0.2 13 low bleb 0 RSR 1 0.567
18 4238872 1 48 2 1 2011 Iotim e/d 2 2 60 0 20 1 23.9 28-04-2016 18-05-16 0.00 18 low bleb 0 LSL 25-05-16 0.00 20
bleb on 
pressure 0 0 01-06-16 0.00 12 low bleb 0 0 08-12-16 0 13 fibrosed bleb Combigan BD 0 2 0.535
19 3850808 2 70 1 1 23-07-2014 Misopt e/d Bidin 2 4 24 0 20 1 23.02 11-03-2016
iris pluggin 
to section, 
FM + 24-03-16 0.80 13
vascularised 
bleb 0 0 31-03-16 0.80 20 low bleb 0 LSL 16-04-16 0.80 14 bleb+ 0 LSL 28-12-16 0.8 17 bleb+
Misopt E/D 
bd 0 2 0.535
20 3761771 2 64 1 1 11-03-2014
Betabrim Lupitros  
Monosopt 1 3 24 0 20 0.3 24.91 11-03-2016 0 05-04-16 0.20 21
fibrosing 
bleb 0 LSL 03-05-16 0.20 12
low diffuse 
bleb 0 LSL 07-05-16 0.20 18 bleb+ 0 LSL 27-10-16 0.2 16 bleb+ Auroprost 0 2 0.502
21 4366420 2 68 1 1 03-10-2016
Auroprost and Alphagan 
Z 1 3 3 3 14 1 24.41 17-01-2017 0 01-02-17 0.00 12 low bleb 0 LSL 16-02-17 0.00 12 low bleb 0 LSL 06-03-17 0 12 good bleb 0 0 16-05-17 0 12 good bleb 0 0 1 0.551
22 4239319 1 70 1 1 12-01-2016 Combigan e/d 2 4 2 0 12 0.3 22.88 18-03-2016 0 02-04-16 0.00 14 bleb+ 0 RS removed 16-04-16 0.00 16 good bleb 0 0 28-04-16 0.00 13 bleb+ 0 0 09-09-16 0 8 good bleb 0 0 1 0.527
23 2332186 1 62 1 1 27-12-2006
Latanoprost+ Dorzox 
11/12/15 1 3 120 120 10 0.2 22.98 19-03-2016 0 04-04-16 0.00 17 low bleb 0 RS removed 16-04-16 0.00 26 low bleb
Dorzox 
BD apical LSL 30-04-16 0.00 8 low bleb
Dorzox 
BD 0 13-09-16 0 10 0 Dorzox BD 0 2 0.519
24 3562974 1 66 1 1 06-06-2013
brimodin Latoprost 
8/9/14 1 3 36 24 15 0.2 22.31 20-01-2016 0 05-02-16 0.20 26 low bleb 0 LSL 19-02-16 0.20 20 low bleb 0 LSL 25-02-16 0.20 19
early 
fibrosis 0 LSL 17-11-16 0.2 15
low to flat 
bleb 0
NEEDLING 
19/3/16 2 0.519
25 4227695 1 65 2 1 29-03-2016 Combigan TravoZ 1 3 7 7 19 0.6 23.42 13-10-2016 0 04-11-16 0.00 17
avascular 
bleb 0 RSR 19-11-16 0.00 14 low bleb 0 LSL 14-12-16 0.00 13 low bleb 0 0 03-05-16 0.00 13 low bleb 0 0 1 0.502
26 4060864 2 67 1 1 15-03-2015 Brimolol 2 4 4 0 20 0.8 24 29-07-2015 0 11-04-16 0.20 12
vascularised 
bleb 0 RS removed 19-04-16 0.00 14 low  bleb 0 0 27-06-16 0.00 18 low bleb
brimolo
l BE 0 19-09-16 0 11 bleb+ Brimolol BE 0 2 0.437
27 4147546 1 61 2 1 19-10-2013
Brimocom e/d + Tovaxo 
19/10/15 1 3 36 5 14 0.8 22.59 23-03-2016 0 07-04-16 0.00 12
vascularised 
bleb 0 RS removed 25-04-16 0.20 16 bleb+ 0 RS removed 21-05-16 0.20 20 bleb+ 0 LSL 30-01-16 0 17 fibrosed bleb
since 
25/4/16 0 2 0.486
28 2277099 1 66 1 1 05-05-2011 Travocom Brinolar 1 3 120 72 10 0.6 23.28 23-03-2016 0 04-04-16 0.00 18
vascularised 
bleb 0 LSL 11-04-16 0.20 5 bleb+ 0 0 25-04-16 0.20 10 bleb+ 0 0 07-02-16 0 14 bleb+ 0 0 1 0.565
29 2704537 1 65 1 2 since 2011 Iotim Careprost 1 3 60 60 22 1.08 22.59 24-03-2016 0 18-04-16 0.00 10 low bleb 0 0 18-04-16 0.00 20 bleb+ 0 LSL 28-04-16 0.00 12 bleb+ 0 LSL 22-12-16 0 16 flat bleb 0 0 1 0.546
30 3395218 2 66 1 1 13-11-2014 Brimolol Monosopt 2 4 24 0 16 0.2 23.64 24-03-2016 0 07-04-16 0.20 16
vascularised 
bleb 0 LSL 26-04-16 0.20 10 bleb+ 0 0 10-05-16 0.20 6 bleb+ 0 0 07-12-16 0.2 18 flat bleb 0 0 1 0.543
31 3426563 1 68 1 1 since 2004 Careprost Brinzox 2014 1 3 144 144 14 0.8 23.2 24-03-2016 0 15-04-16 0.20 12 flat bleb 0 LSL 15-04-16 0.00 12 low bleb 0 LSL 29-04-16 0.00 15 low bleb 0 0 25-01-16 0 15 low bleb 0 0 1 0.535
32 3811489 2 66 2 2 since 2011 Careprost 1 1 60 60 17 0.3 24.17 25-03-2016 0 09-04-16 0.00 9 diffuse bleb 0 0 19-04-16 0.00 12 tenons cyst 0 RS removed 30-04-16 0.00 13 tenons cyst 0
Tenons 
cyst - 
needling 
on 
30/7/16 05-01-17 0 15 bleb+ 0 0 2 0.502
33 4228421 1 65 2 1 since 2014 Timolet 2 2 24 0 17 0.3 22.61 26-08-2016 0 25-03-16 0.30 14 bleb+ 0 0 09-04-16 0.30 12 bleb+ 0 0 26-04-16 0.30 12
flat 
vascularise
d bleb 0 LSL 16-07-16 0.2 12 bleb+ 0 0 1 0.568
34 3924751 2 78 1 2 22-11-2014 Timolet 2 2 24 0 13 0.6 24.12 31-03-2016 0 15-04-16 0.02 10
vascularised 
bleb 0 LSL 29-04-16 0.02 11 bleb+ 0 LSL 24-05-16 0.20 8 bleb+ 0 0 22-12-16 0.2 9 bleb+ 0 0 1 0.535
35 3779547 2 56 1 1 09-04-2014 Timolet 2 2 24 0 16 0.2 22.56 01-04-2016 0 02-05-16 0.00 13 diffuse bleb 0 LSL 18-07-16 0.00 18 low bleb 0 LSL 18-08-16 0.00 18 low bleb 0 0 18-09-16 0 12 bleb+ 0 0 1 0.535
36 4236318 1 68 1 1 11-07-2013 Iotim e/d BE 2 2 36 0 20 0.8 23.53 01-04-2016 0 15-04-16 0.20 11 low bleb 0 0 25-04-16 0.20 10 low bleb 0 LSL 30-04-16 0.20 10
vascularise
d bleb 0 LSL 18-05-16 0.2 8 low bleb 0 0 1 0.519
37 3292957 1 68 1 2 19-12-2011
Lumigan e/d Combigan 
2012 1 3 60 60 12 0.3 23.41 05-04-2016 0 21-04-16 0.00 16 bleb+ 0 RSR 05-05-16 0.00 14 bleb+ 0 apical LSL 24-05-16 0.00 8 bleb+ 0 0 30-01-17 0 6 bleb+ 0 0 1 0.469
38 3802281 1 56 2 1 23-04-2015 Glucomol BD 2 2 12 0 19 0.5 22.1 07-04-2016 0 18-04-16 0.00 9 low bleb 0 0 28-04-16 0.00 12 0 0 RSR 01-06-16 0.20 13 low bleb 0 LSL 19-07-16 0.2 12 low bleb 0 0 1 0.486
39 3821151 2 69 1 2 09-06-2014 Glucomol BD 2 2 24 0 15 0.3 23.85 09-04-2016 0 23-04-16 0.00 20 low bleb 0 RSR 09-05-16 0.00 14
fibrosed 
bleb
Betabri
m e.d LSL 01-07-16 0.00 12
low 
fibrosed 
bleb
Betabri
m e.d LSL 22-11-16 0 13 low bleb Betabrim e.d RSR 2 0.535
40 4139310 1 61 1 1 06-10-2015 Bimat TCibrim Z 1 3 6 6 38 0.6 24.16 15-04-2016 0 07-05-16 0.60 12 low bleb 0 0 08-06-16 0.50 17 bleb+ 0 LSL
LOST FOR 
FOLLOW-
UP 0 0.568
41 2276492 2 60 2 1 30-08-2007 Lumigan Alphagan 2014 1 3 108 108 16 0.3 23.03 16-04-2016 0 22-04-16 0.00 30
bleb raised 
on digital 
massage 0 0 28-04-16 0.00 18
low 
vascularise
d bleb 0 LSL
LOST FOR 
FOLLOW-
UP 0
42 4241263 1 55 2 1 15-01-2016 Lopres e.d BD 2 2 3 0 18 1 23.44 19-04-2016 0 10-05-16 0.00 12
mild 
conjunctival 
retraction 0 1RSR 24-05-16 0.00 12
conjunctiva
l retraction 12 LSL 23-06-16 0.00 14
vascularise
d  bleb 0 LSL 07-11-16 0 12 low bleb 0 0 1 0.537
Follow Up 2 WEEKS Follow Up 1 month Follow Up 3 months Last follow-up 6 months
43 4238872 2 48 2 1 2011 Iotim e/d 2 2 60 0 30 1 23.93 29-03-2016 0 12-04-16 0.00 26
bleb raised 
on digital 
massage 0
2RS 
removed 27-04-16 0.00 15 low bleb apical LSL 11-05-16 0.00 24 flat bleb
Bleb 
needling(
11/5/16) 08-12-16 0 16 flat bleb
Combigan 
BD, Travatan 
e/d HS 0 2 0.519
44 4092202 1 68 1 1 29-01-2015 Combigan 2 4 12 0 14 0.5 26.96 03-05-2016 0 18-05-16 0.00 11 low bleb 0 0 04-06-16 0.00 10
diffuse 
bleb 0 0 27-06-16 0.00 8
diffuse 
bleb 0 0 21-09-16 0 8 bleb+ 0 RS removal 1 0.535
45 802956 1 63 1 1 10-04-2009 Careprost Iobrim 1 3 84 84 12 0.6 25.1 10-05-2016 0 25-05-16 0.00 26
low diffuse 
vascularised 
bleb 0 RSR 03-06-16 0.00 28
thick 
walled flat 
vascularise
d bleb 0 LSL 13-06-16 0.00 22
flat 
vascularise
d bleb
Iobrim 
TID
Bleb 
needling 
(6/8/16) 04-11-16 0 12 low bleb
Lopres e/d  
BD 0 2 0.502
46 4198723 1 75 2 2 12-11-2015 Betabrim BD, Dorzox TDS 2 4 3 0 20 1.08 23.04 12-02-2016 0 01-03-16 0.00 32 flat bleb 0
apical 
suture 18-05-16 0.00 21 bleb+
Cibrim Z 
BD 0 07-06-16 0.00 20 low bleb
Cibrim 
Z bd 
and 
Dorzox 
TID
loose 
suture 
removal 21-02-17 0 20
AlphaganP + 
Tovaxo 0 2 0.551
47 4198723 2 75 2 2 Betabrim BD, Dorzox TDS 2 4 4 0 21 0.6 23.01 11-05-2016
early FM, 
shallow AC 20-05-16 0.30 9
vascularise 
bleb 
choroidal 
folds
Flupre
d e/d 
QID
360d 
shallow CD 07-06-16 0.00 20 low bleb
Alphaga
n P BE 06-09-16 0.00 18
Alphag
an P bd 0 0 17 AlphaganP 2 0.548
48 4145012 2 60 2 1 01-06-2015 Duobrom Travatan 1 3 4 4 16 1 22.1 17-10-2015 0 30-05-16 0.00 14 bleb+ LOST FOR 0 0.502
49 4004382 2 71 2 2 29-04-2015 Combigan 2 4 12 0 20 0.5 21.91 31-05-2016 0 15-06-16 0.00 13
vascularised 
bleb 0 LSL 30-06-16 0.00 22 flat bleb 0 LSL 15-07-16 0.00 16 flat bleb 0 0 20-08-16 0 12 flat bleb 0 0 1 0.519
50 3835900 1 63 1 1 30-06-2014 Combigan 2 4 24 0 21 0.8 23.36 18-08-2016 0 02-09-16 0.00 20 low bleb 0 1RS 23-09-16 0.00 15 bleb+ 0 RSR 04-10-16 0.00 18 low bleb 0 LSL 15-02-17 0 19 flat bleb 0 0 1 0.502
51 3490176 1 75 2 1 13-06-2013 Brinolar 2 2 36 0 21 0.8 23.59 18-08-2016 0 02-09-16 0.00 10 low bleb 0 0 09-09-16 0.00 16 low bleb 0 1RSR 23-09-16 0.00 9 0 0 0 30-01-17 0 12 low bleb 0 0 1 0.535
52 2565337 2 64 2 1 05-08-2015 Combigan BD 2 4 12 0 16 0.5 22.76 26-08-2016 0 08-09-16 0.00 15 low bleb 0 RSR 17-09-16 0.00 17
low bleb, 
localised 
DM strip 0 LSL 01-10-16 0.00 15 bleb+ 0 0 09-12-16 0 10 low bleb 0 0 1 0.56
53 1969420 2 68 1 1 07-02-2014 Timoblu e/d 2 2 24 0 17 0.2 22.71 22-09-2016 0 07-10-16 0.00 12
vascularised 
bleb 0 LSL 14-10-16 0.00 17
low bleb, 
iris in 
ostium s/p 
LSL 0 0 18-10-16 0.00 15
low bleb, 
peaking 
pupil
Iris 
repositi
oning 
on 
21/10/
16 0 12-11-16 0 13 low bleb 0 0 1 0.568
54 2299676 1 65 1 1 23-05-2008 Careprost Brimosun 1 3 96 96 16 0.6 22.5 21-09-2016 0 06-10-16 0.00 18 bleb+ 0 RSR
LOST FOR 
FOLLOW UP 0 0.502
55 4077389 1 57 2 1 08-07-2015
Latoprost RT Lopres 
16/3/16 1 3 12 12 21 15 22.57 21-10-2016 0 09-11-16 0.00 12
bleb not 
raised by 
massage 0 LSL 23-11-16 0.00 12 low bleb 0 add LSL 25-01-17 0.00 14 low bleb 0 0 25-05-17 0.00 14 low bleb 0 0 1 0.549
56 3376630 1 81 1 2 30-06-2016
Lopres 0.5% Alphagan Z 
27/7/16 2 4 4 0 20 1.07 22.7 14-10-2016 0 25-10-16 0.00 26
vascularised 
bleb 0 LSL 10-11-16 0.00 9
bleb not 
raising - 
vascularise
d 0 apical LSL 10-12-16 0.00 12 bleb+ 0 0 10-04-17 0.00 12 bleb+ 0 0 1 0.471
57 4290004 1 45 1 1 24-05-2016
Brimocom e/d Travo z 
1/7/16 1 3 5 3 16 1 22.62 22-10-2016 0 07-11-16 0.00 17 bleb+ 0 0 18-11-17 0.00 18
bleb not 
raise with 
massage 0 LSL 20-12-16 0.00 18 bleb+ 0 LSL 20-04-17 0.00 18 bleb+ 0 0 1 0.551
58 4366420 1 68 1 1 30-07-2016 Combigan e/d 2 4 3 0 16 1 24.5 13-10-2016 0 04-11-16 0.20 23
avascular 
bleb 0 LSL 18-11-16 0.20 11 bleb+ 0 LSL 02-12-16 0.00 12 good bleb 0 0 16-02-17 0 12 good bleb 0 0 1 0.535
59 4227695 2 65 2 1 25-02-2016 Alphagan Z stopped 1 3 4 3 16 0.6 23.35 30-06-2016 0 21-07-16 0.00 13
bleb on 
pressure 0 RSR 01-08-16 0.00 12
diffuse 
bleb 0 RSR 15-08-16 0.00 15 bleb+ 0 LSL 14-12-16 0 10 good bleb 0 0 1 0.486
60 4349283 2 60 1 1 08-07-2016 Travoz+Brimolol 1 3 12 3 22 0.5 24.76 18-10-2016 0 07-11-16 0.00 16
vascularised 
bleb 0 LSL 21-11-16 0.00 12 low bleb 0 0 09-12-16 0.00 16 low bleb 0 LSL 09-01-17 0 16
raised mildly 
vascularised 
bleb 0 0 1 0.502
61 4374851 1 47 2 1 01-01-2014 Combigan and Brinolar 2 4 24 0 10 1 23.02 15-10-2016 0 25-10-16 0.20 15 flat bleb 0 1RS 07-11-16 0.20 12 low bleb 0 RSR 12-12-16 0.20 8 low bleb 0 0 16-01-17 0.2 8 low bleb 0 0 1 0.519
62 3376630 1 76 1 2 30-06-2016 Lopres 2 2 4 0 18 0.5 22.7 14-10-2016 0 25-10-16 0.00 26
low 
vascularised 
bleb 0 LSL 10-11-16 0.00 9
vascularise
d bleb 0 LSL 10-12-16 0.00 12 bleb 0 0 14-04-17 0.00 12 bleb 0 0 1 0.472
63 4098634 1 65 1 1 07-01-2016 Combigan 2 4 7 0 28 0.6 23.58 03-08-2016 0 11-08-16 0.20 24
flat bleb 
with 
vascularizati
on 0 RSR 22-08-16 0.20 18 bleb+ 0 RSR 08-09-16 0.00 14 low bleb 0 LSL 23-09-16 0 14 diffuse bleb 0 0 1 0.469
64 3974337 2 71 2 1 15-04-2015 Timolet Alphagan Z 2 4 12 0 24 0.5 22.97 24-11-2016 0 09-12-16 0.20 16 low bleb 0 LSL 20-12-16 0.00 16 low bleb
Lopres 
BD 0 10-01-17 00-01-00 14.00 low bleb
Lopres 
BD 0 10-05-17 0 12 low bleb Lopres BD 0 2 0.536
65 4262813 1 64 1 2 30-05-2016 Latacom CF 1 1 7 7 9 0.2 23.13 10-12-2016 0 26-12-16 0.20 12 diffuse bleb 0 0 10-01-17 0.00 8
diffuse 
bleb 0 0 24-01-17 0.00 10
diffuse 
bleb 0 0 17-02-17 0.2 10 diffuse bleb 0 0 1 0.47
66 2498075 2 45 1 1 15-11-2007 Combigan+ Latomost 1 3 108 108 17 0.5 23.43 25-11-2016 0 05-12-16 0.50 2
diffuse bleb 
SHALLOW 
CD 0 0 15-12-16 0.20 14
low 
vascularise
d bleb 0 LSL 22-12-17 0.00 31 cystic bleb
Combig
an 
Latopro
st LSL 14-02-17 0 10 bleb+
Cibrim T& 
Auroprost RT 0 2 0.502
67 2142189 1 66 1 1 05-11-2005 Latoprost Iobrim 1 3 132 120 10 0.5 23.35 27-08-2016 0 12-09-16 0.20 16 bleb+ 0 RSR 26-09-16 0.00 19
bleb not 
raised 0 RSR LSL 13-10-16 0.00 19 bleb+ 0 apical LSL 24-01-17 0 14 low bleb 0 0 1 0.519
68 4391938 2 50 2 1 21-08-2016 TravoT 1 1 3 3 36 0.3 22.96 01-11-2016 0 12-11-16 0.20 16 bleb 0 21-11-16 0.20 18
good 
diffuse 
bleb 0 RSR 10-03-17 0.30 20
low diffuse 
bleb 0 apical LSL 10-04-17 0.30 16
low diffuse 
bleb 0 0 1 0.453
69 4325781 2 52 1 1 05-07-2016 Timolet 0.5% 2 2 4 0 20 1 25.72 23-11-2016 0 02-12-16 0.20 18 low bleb 0 RSR 09-12-16 0.20 15 bleb+ 0 LSL
LOST TO 
FOLLOWUP 0 0.519
70 3643583 1 53 2 1 19-08-2013 Timolet 2 2 36 0 16 0.2 23.41 29-11-2016 0 14-12-16 0.00 8 bleb 0 0 26-12-16 0.00 8 good bleb 0 0 02-01-17 0.00 11
good 
diffuse 
bleb 0 0 11-02-17 0 12 bleb+ RSR 0 1 0.486
71 4273791 1 71 1 2 03-05-2016 Betabrim 2 4 7 0 22 0.2 22.47 22-12-2016 0 07-01-17 0.20 12 bleb+ 0 LSL 18-01-17 0.20 22 good bleb+ 0 LSL 02-02-17 0.20 18 good bleb 0 RSR 02-03-17 0.2 20 bleb+ 0 LSL 1 0.551
72 2651661 1 54 2 1 05-01-2015 Travo Z 1 1 19 19 18 0.6 22.27 28-08-2016 0 07-09-16 0.20 18
vascularised 
bleb 0 LSL 21-09-16 0.00 14
vascularise
d bleb 0 LSL 21-10-16 0.00 14
avascular 
bleb
Misopt 
e/d BE RSR 19-01-17 0 12 bleb+ Tovaxo T HS 0 2 0.486
74 2757272 1 61 1 1 14-04-2015 Latoprost Timolol 1 3 16 16 39 0.3 23.67 22-09-2016 0
Case 
sheet not 
available 0
75 3918480 2 59 2 1 14-02-2015
Brimocom Dortas 5/5/16 
Auroprost RT 1 3 24 4 13 1 23.66 10-09-2016 0 09-09-16 0.20 13
vascularised 
bleb 0 RSR 03-10-16 0.20 18 low bleb 0 LSL 22-11-16 0.2 13
avascualar 
bleb 0 0 22-03-17 0.2 20 bleb+
Brimocom 
BD 0 2 0.519
76 4236626 1 73 1 2 17-06-2016 Travo combigan Dorzox 1 3 3 3 10 0.3 22.88 03-09-2016 0 28-09-16 0.30 10
vascularised 
low bleb 0 LSL 26-10-16 0.20 12 low bleb 0 0
LOST FOR 
FOLLOW-
UP 0 0.453
77 4431267 1 55 2 1 29-11-2016 Glucomol BD 2 2 4 0 16 0.6 21.85 31-03-2017 0 11-04-17 0.20 18
bleb not 
raised on 
digital 
massage 0 LSL 25-04-17 0.20 16 low bleb 0 LSL 09-05-17 0.00 16 low bleb 0 0 30-06-17 0 15 bleb+ 0 0 1 0.502
78 2720431 2 55 1 1 20-01-2009
Ganfort Dorzox 14/7/15 
Xalacom HS 1 3 84 84 20 0.5 24.66 18-02-2017 0 27-03-17 0.00 23
flat vascular 
bleb 0 0 06-04-17 0.00 22 bleb+ 0 Goniopuncture 20-04-17 0.00 16 no bleb
Cibrim 
T 0 29-06-17 0 18 bleb+ Cibtim T 0 2 0.561
79 4405629 1 53 1 1 22-10-2016 Lopress 2 2 5 0 18 0.8 24.98 16-03-2017 0 07-04-17 0.00 13
vascularised 
bleb 0 LSL 22-04-17 0.00 10 bleb 0 0 25-05-17 0.00 10 low bleb 0 RSR 22-07-17 0 12 bleb 0 0 1 0.551
80 4446514 2 75 1 1 Dec-16 Bidin LS 2 2 4 0 14 0.3 23.26 19-04-2017 0 05-05-17 0.00 16 low bleb 0 LSL 22-05-17 0.00 4
diffuse 
bleb 0 0 07-06-17 0.00 4
diffuse 
bleb 0 0 07-07-17 0 10 diffuse bleb 0 0 1 0.551
81 4121853 2 68 2 1 11-06-2015 Misopt 2 2 9 0 20 0.6 22.72 16-03-2017 0 01-03-17 0.00 16
elevated flat 
vascularised 
bleb 0 LSL 15-03-17 0.00 11
vascularise
d bleb 0 LSL 01-07-17 0.00 10 low bleb 0 0 01-08-17 0.00 10 low bleb 0 0 1 0.535
82 3487105 2 53 1 1 2013 Travo Z, Timolet OD 1 3 48 48 23 0.3 23.68 25-04-2017 0 11-05-17 0.00 22 diffuse bleb 0 RSR 25-05-17 0.00 16
mild 
conjunctiva
l retraction 0 LSL 13-07-17 0.00 12
avascular 
bleb 0 0 11-08-17 0.00 13
avascular 
bleb 0 0 1 0.502
83 4309759 2 81 1 2 18-05-2016 shift to Betabrim Dorzox 2 4 3 0 20 0.5 22.73 11-08-2016 0 24-08-16 0.20 12
bleb on 
pressure 0 0 13-09-16 0.20 12 low bleb+ 0
anchoring 
suture release 11-10-16 0.20 12 low bleb 0 SR 19-12-16 0.2 12 low bleb 0 0 1 0.519
84 4476117 2 67 1 1 2015 Combigan 2 4 24 0 18 0.5 22.74 16-03-2017 0 01-04-17 0.00 19
bleb raised 
on digital 
massage 0 LSL 21-04-17 0.00 20
bleb 
fibrosis
Combiga
n 0 11-07-17 0.00 13
fibrosed 
bleb
Combig
an BD 0 07-08-17 0 15 fibrosed bleb Comigan BD 0 2 0.545
86 3530522 2 61 2 1 2014 Dortas T 2 4 36 0 16 0.8 22.91 06-11-2016 0 21-01-16 0.00 19 diffuse bleb 0 RSR 04-02-16 0.00 11
diffuse 
bleb with 
mild 
vascularisa
tion 0 0 02-03-16 0.00 13 bleb+ 0 0 12-07-17 0 19 diffuse bleb Lopres 0 2 0.486
87 3825640 1 60 1 1 30-07-2014 Brimolol Latoprost RT 1 3 24 24 12 0.3 23.26 09-01-2016 0 25-01-16 0.00 20 flat bleb 0 RSR 09-02-16 0.00 20 flat bleb+ 0 RSR 03-03-16 0.00 16 low bleb 0 LSL 28-06-16 0 13 low bleb 0 0 1 0.519
88 4189015 1 73 1 1 28-10-2015 Dorsum T 2 4 3 0 18 0.6 22.6 09-01-2016 0 18-01-16 0.20 19 low bleb 0 RSR 25-01-16 0.00 12 low bleb 0 0 08-02-16 0.00 14 bleb+ 0 0 11-08-16 0 20 low bleb Auroprost RT 0 2 0.502
89 3066215 1 76 1 1 07-05-2015 Misopt 2 2 8 0 14 0.2 22.4 09-01-2016 0 23-01-16 0.30 10
low 
vascularised 
bleb 0 RSR 04-02-16 0.20 10 low bleb 0 RSR 18-02-16 0.20 14 flat bleb 0 LSL 31-01-17 0.2 10 low bleb 0 0 1 0.486
90 3990442 2 68 1 1 05-03-2015 Brimolol 2 4 10 0 18 1 23.38 08-01-2016 0 23-01-16 0.20 24 bleb+ 0 LSL 09-02-16 0.00 18 low bleb 0 LSL 09-03-16 0.00 13 bleb+ 0 0 16-06-16 0 7 bleb+ 0 0 1 0.551
91 4118987 1 62 1 2 2013 Auroprost RT 1 3 36 36 20 0.6 23.18 11-01-2016 0 26-01-16 0.20 17
bleb raised 
on digital 
massage 0 LSL 12-02-16 0.20 8 bleb+ 0 0 12-03-16 0.20 12 bleb+ 0 LSL 28-12-16 0.2 18 elevated bleb 0 0 1 0.497
92 4162454 1 46 1 1 16-10-2015 Brimolol 2 4 3 0 10 0.2 24.32 12-01-2016 0 27-01-16 0.00 14 bleb+ 0 RSR 11-02-16 0.00 13 low bleb 0 RSR 09-03-16 0.00 20
?tenons 
cyst 0
Bleb 
needling 11-08-16 0 16 low bleb 0 0 2 0.495
93 4133959 1 70 2 1 30-09-2015 Iobrim 2 2 4 0 11 0.8 22.42 12-01-2016 0 23-01-16 0.20 10 flat bleb 0 LSL 06-02-16 0.20 10 low bleb 0 LSL 20-02-16 0.20 14 bleb+ 0 LSL 11-08-16 0.2 8 good bleb+ 0 0 1 0.502
94 4188706 2 58 1 1 28-10-2015 Brimolol 2 4 3 0 28 1.01 22.67 19-01-2016
cheese 
wiring flap 03-02-16 0.20 28
vascularised 
bleb 0 RSR 17-02-16 0.00 28 low bleb 0 LSL 04-03-16 0.00 26
fibrosed 
bleb 0 LSL 17-03-16 0 24 low bleb
Combigan 
and Dorzox
Bleb 
needling 2 0.584
95 4185201 2 61 2 1 23-12-2015 Aurotim e/d 2 2 9 0 11 0.8 22.89 15-09-2016 0 30-09-16 0.20 9 flat bleb 0 LSL 07-10-16 0.20 10
diffuse 
bleb 0 0 24-10-16 0.00 10 bleb + 0 LSL 27-01-17 0 15 bleb+ 0 0 1 0.47
96 4095110 2 74 1 1 03-08-2015 Timolet OD 2 2 5 0 20 0.6 22.97 19-01-2016 0 03-02-16 0.20 20
vascularised 
bleb 0 RSR 10-02-16 0.20 15 good bleb 0 LSL 02-03-16 0.20 16 good bleb 0 0 02-06-16 0.20 15 good bleb 0 0 1 0.535
97 4185201 1 61 2 1 23-12-2015 Aurotim e/d 2 2 3 0 10 0.6 22.99 23-01-2016 0 08-02-16 0.20 12 low bleb 0 RSR 17-02-16 0.20 7 bleb + 0 LSL 31-03-16 0.20 12 flat bleb 0 0 23-06-16 0.2 18 bleb+ 0 0 1 0.47
98 3907685 1 57 2 1 27-11-2014 Auroprost RT e/d 2 4 24 24 14 0.5 22.04 08-02-2016 0 08-02-16 0.30 16
vascularised 
bleb 0 LSL 22-02-16 0.30 16 flat bleb 0 LSL 15-04-16 0.30 13 bleb+ 0 0 17-10-16 0.3 14 bleb+ 0 0 1 0.502
99 4129116 1 82 1 1 24-09-2015 Betabrim 2 4 4 0 17 0.3 23.06 28-01-2016 0 08-02-16 0.20 12 bleb+ 0 LSL 19-02-16 0.20 11 bleb+ 0 LSL 21-04-16 0.00 12 bleb+ 0 0 12-05-17 0 15 bleb 0 0 1 0.535
100 2384819 2 69 1 1 05-08-2015 Alphagan P 2 2 4 0 20 0.2 22.63 21-01-2016 0 17-02-16 0.00 16 low bleb 0 LSL 09-03-16 0.00 16 low bleb 0 LSL 06-04-16 0.00 13 flat bleb
Nuclear 
fragment 
removal 09-08-17 0 13 low bleb 0 0 1 0.551
101 2286967 2 63 2 1 08-10-2008 Ganfort 1 3 96 96 20 0.5 24.61 20-01-2016 0 04-02-16 0.00 23 low bleb 0 LSL 16-02-16 0.00 22
bleb 
fibrosis 0 LSL 26-02-16 0.00 20 low bleb Ganfort LSL 16-06-16 0 12 low bleb Ganfort 0 2 0.519
102 4182805 1 81 2 1 19-10-2015 Glucomol 2 2 3 0 16 0.8 23.06 20-01-2016 0 04-02-16 1.00 30 bleb+
Gluco
mol LSL 11-02-16 1.00 12 bleb+
Glucom
ol LSL 18-02-16 1.00 10 bleb 0 LSL 11-05-16 1 13 low bleb 0 0 3 0.502
103 4138183 1 69 2 1 05-10-2015 Glucomol 2 2 4 0 15 0.6 24.9 26-02-2016 0 10-02-16 0.20 11
vascularised 
bleb 0 RSR 22-02-16 0.20 22 low bleb 0 LSL 07-03-16 0.20 12
diffuse 
bleb 0 0 08-08-16 0.2 14 bleb+ Bidin T 0 2 0.535
104 3001234 2 69 1 1 04-05-2015 Ganfort 1 3 8 8 18 0.6 23.76 23-01-2016 0 11-02-16 0.30 25
vascularised 
bleb 0 RSR 01-03-16 0.20 15 bleb+ 0 0 13-08-16 0.00 48
diffuse 
bleb
Azopt 
e/d BD, 
Iopar 
SR 0 26-09-16 0 38 bleb+
Alphagan Z, 
Ganfort, 
Azopt AADI 3 0.519
105 4198974 2 65 1 1 28-11-2015 Latoprost RT Bidin 1 3 3 3 19 0.6 22.98 05-02-2016 0 20-02-16 0.00 20 low bleb 0 RSR 01-03-16 0.00 28 flat bleb 0 LSL 08-03-16 0.00 16
low diffuse 
bleb 0 LSL 23-03-16 0 18 diffuse bleb 0 LSL 1 0.535
106 4092704 2 64 2 1 05-09-2015 Betabrim 2 4 4 0 18 0.6 22.41 27-01-2016 0 11-02-16 0.20 15 diffuse bleb 0 RSR 02-03-16 0.00 20 broken RS 0 LSL 24-03-16 0.00 18
diffuse 
bleb 0 LSL 13-04-16 0 15
avascular 
bleb Lacoma PF 0 2 0.545
107 3826287 2 50 1 1 16-08-2014 Combigan 2 4 5 0 24 0.8 22.59 27-01-2016 0 11-02-16 0.20 18 bleb+ 0 RSR 26-02-16 0.00 14 good bleb 0 0 08-03-16 0.00 14
avascular 
bleb 0 0 01-07-16 0 15 bleb+ 0 0 1 0.555
108 4161022 1 76 2 1 13-11-2015 Bidin LS 2 2 3 0 16 1.01 22.94 02-02-2016 0 10-02-16 0.00 12
vascularised 
bleb 0 0 17-02-16 0.00 13 low bleb 0 LSL 02-03-16 0.00 18 low bleb 0 LSL 03-09-16 0 13 bleb+ Bidin LS 0 2 0.491
109 4309759 1 81 1 2 18-07-2016 shift to Betabrim 2 4 8 0 19 0.5 22.98 21-03-2017 0 05-04-17 0.20 20 low bleb 0 LSL 20-04-17 0.00 12 bleb+ 0 0 27-03-16 0.00 14 bleb+ 0 0 26-07-16 0.00 13 bleb+ 0 0 1 0.519
110 3990442 1 68 1 1 09-04-2015 Dortas 2 4 14 0 16 0.5 23.55 26-06-2016 0 18-07-16 0.00 30 flat bleb 0 LSL 01-08-16 0.00 16
avascular 
bleb 0 LSL 23-08-16 0.00 10
avascular 
bleb 0 0 15-10-16 0 9
avascular 
bleb 0 0 1 0.535
111 4118987 1 62 1 2 2013
Auroprost Rt 7/9/15 add 
Betabrim and Dortas 1 3 36 36 15 0.8 23.2 14-05-2016 0 10-06-16 0.20 20 bleb+ 0 LSL 28-06-16 0.20 16 bleb+ 0 0 28-07-16 0.20 15 bleb+ 0 0 28-12-16 0 20 elevated bleb 0 0 1 0.501
